University of Massachusetts Amherst

ScholarWorks@UMass Amherst
Doctoral Dissertations

Dissertations and Theses

July 2016

Bioengineered Platforms to Study Carcinoma Cell Response to
Drug Treatment
Thuy V. Nguyen
University of Massachusetts Amherst

Follow this and additional works at: https://scholarworks.umass.edu/dissertations_2
Part of the Biochemical and Biomolecular Engineering Commons, Biological Engineering Commons,
Biomaterials Commons, and the Cancer Biology Commons

Recommended Citation
Nguyen, Thuy V., "Bioengineered Platforms to Study Carcinoma Cell Response to Drug Treatment" (2016).
Doctoral Dissertations. 654.
https://doi.org/10.7275/8055558.0 https://scholarworks.umass.edu/dissertations_2/654

This Open Access Dissertation is brought to you for free and open access by the Dissertations and Theses at
ScholarWorks@UMass Amherst. It has been accepted for inclusion in Doctoral Dissertations by an authorized
administrator of ScholarWorks@UMass Amherst. For more information, please contact
scholarworks@library.umass.edu.

BIOENGINEERED PLATFORMS TO STUDY CARCINOMA CELL RESPONSE
TO DRUG TREATMENT

A Dissertation Presented
by
THUY VINH LUONG NGUYEN

Submitted to the Graduate School of the
University of Massachusetts Amherst in partial fulfillment
of the requirements for the degree of

DOCTOR OF PHILOSOPHY

May 2016

Department of Chemical Engineering

© Copyright by Thuy Vinh Luong Nguyen 2016
All Rights Reserved
Portions of Chapter 1 © 2012 American cancer society, Inc. © 2013 IOP publishing Ltd.
© 2012 Elsevier, Inc. © 2004 and 2013 MacMillan Publishers Inc.
Portions of Chapters 2 and 3 © 2013 American Chemical Society
Portions of Chapter 4 © 2014 Elsevier, Inc.

BIOENGINEERED PLATFORMS TO STUDY CARCINOMA CELL RESPONSE
TO DRUG TREATMENT

A Dissertation Presented

by

THUY VINH LUONG NGUYEN

Approved as to style and content by:

Shelly R. Peyton, Chair

Neil Forbes, Member

Ryan Hayward, Outside Member

John Klier, Department Head
Department of Chemical Engineering

DEDICATION

To my Father, my Mother, and my Sister,
Your love and support made this possible

ACKNOWLEDGEMENTS
First, I am very grateful to my graduate advisor, Dr. Shelly Peyton, for taking me
in as her first graduate student even though I did not have any previous biology
knowledge. Dr. Peyton has been a great advisor and mentor, and I would like to thank her
for her tremendous support throughout my time in graduate school. She has always been
willing to help me when I need her, such as reviewing my abstracts for conferences,
giving me feedback on my presentations, reviewing my manuscripts, etc. Her passion for
science was very inspiring to me and the other students in lab. Being the first graduate
student in her lab is a challenging and fantastic experience, and I have gained great
experience through the journey. The training in her lab has changed me in many ways,
and I have been excited to see myself improving over the years in many areas, including
technical skills, presenting and public speaking skills, organizational skills, most
importantly, being a better research scientist. She has been very reliable and always
giving me honest and constructive advice to improve my weaknesses and my research.
For all of this, I am extremely grateful to have a mentor and advisor like Dr. Peyton.
I am very grateful to my colleagues in Dr. Peyton's lab, especially past members:
Dr. William Herrick, Dannielle Ryman, and current members: Dr. Samuel Polio, Dr.
Maria Gencoglu, Dr. Katie Bittner, Lauren Barney, Lauren Jansen, Alyssa Schwartz,
Elizabeth Brooks, and Sualyneth Galarza, as well as the great undergraduates whom I had
the opportunity to mentor (Marianne Sleiman, Timothy Moriarty, and Danielle
LaValley). I thank each of them for their tremendous support such as technical
suggestions, writing and presenting critiques, technical assistance and collaborations. I
have enjoyed our conversations regarding research and life and our sharing of fun
v

moments in the lab and at conferences. Besides, Dannielle, Lauren B., Lauren J., Alyssa,
and Elizabeth have always kept me in check with everything in lab. Will, Lauren B.,
Alyssa, and Elizabeth have helped me place orders or allowed me to use their procards to
order materials for my research. I also thank many other undergraduates that I have
interacted with (Tyler Vlass, Erinn Dandley, Prateek Katti, Maxsimillyan Nowak, Aidan
Gilchrist, Michael Grunwald, Shayna Nolan, Thomas McCarthy, and John MacMunn);
my interactions with them have made my experience in the Peyton lab memorable. I hope
to stay in touch with everyone for many years to come.
I would like to thank the members of my thesis committee, Dr. Neil Forbes and
Dr. Ryan Hayward for their support. They spent time to discuss with me about my
research progress and challenged me to think outside the box. My meetings with them
were very informative and enlightening.
I am grateful to the University of Massachusetts Amherst, especially the
department of Chemical Engineering, for the financial support. I would like to thank Dr.
Barry Siadat and Mrs. Afsaneh Siadat for their generous donation, which has funded my
stipend and fees for the last couple years of my graduate study. I also would like to
acknowledge other funding sources such as the National Institute of Health and the
Materials Research Science and Engineering Center.
I also would like to thank the Chemical Engineering departmental staff members:
Marie Wallace, Amity Lee-Bradley, Anshalee Guarnieri and Lauren O’Brien. I
appreciate their hard work to ensure my on-time payment, supply ordering, travel
reimbursement, and other related paperwork.

vi

Finally, I would like to thank my family for their continuing support, love, and
encouragement. Specifically, I am very grateful to my parents and sister for their
financial and emotional support. My parents have given me a great financial support from
buying me a brand new car to paying for my meal plans and airline tickets to visit home.
They have always tried to make sure that I have a comfortable life and everything that I
need to pursue my passions. My sister has always been a huge part of my life. Whether it
was her phone calls or fun text messages showing her cat and dogs, little things like those
have kept me sane when my work life got crazy.

vii

ABSTRACT

BIOENGINEERED PLATFORMS TO STUDY CARCINOMA CELL RESPONSE
TO DRUG TREATMENT

MAY 2016
THUY VINH LUONG NGUYEN
B.S., GEORGIA INSTITUTE OF TECHNOLOGY
M.S., GEORGIA INSTITUTE OF TECHNOLOGY
PH.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Shelly R. Peyton

The tumor extracellular matrix (ECM) plays an important role in facilitating
tumor growth and mediating tumor cells' resistance to drugs. However, during drug
development, potential chemotherapeutics are screened in plastic plates, which lack
relevant ECM physicochemical cues. In order to improve drug development process, this
dissertation includes the development of relevant 2D and 3D biomaterial systems that can
be used to study carcinoma cell response to drug treatment.
A novel poly(ethylene glycol)-phosphorylcholine (PEG-PC) high-throughput
biomaterial platform was developed to study how the ECM mechanochemical properties
affect cancer cells' response to drug. The PEG-PC biomaterial is optically transparent,
has a mechanical range from 1 to 10,000 kPa in Young's modulus, and allows easy
coupling of cell adhesive proteins. When testing several breast and liver cancer cell lines

viii

on PEG-PC gels that had different stiffnesses and integrin-binding sites, there was a
significant increase in drug resistance with increasing substrate stiffness. It was found
that this stiffness-induced drug resistance was independent of Rho-ROCK and EGFR
signaling, but co-administration of a β1 integrin antibody, or an inhibitor to JNK, with
sorafenib effectively eliminated the stiffness-mediated sorafenib resistance. Finally, 3D
hydrogel systems, poly(N-isopropylacrylamide)-PEG (PNIPAAm-PEG) and PEGMaleimide, were utilized to create multi-cellular spheroids to study drug resistance in 3D.
Both SkBr3s and MDA-MB-231s were tested with sorafenib, lapatinib, temsirolimus, and
doxorubicin across varying moduli and geometry (plastic, 2D and 3D hydrogels,
spheroid) in different medium conditions. For some drugs, the change in platform or
medium was found to have the largest effect on the variation of the IC-50 than the change
in modulus. Specifically, the IC-50s varied the most when SkBr3s were treated with
sorafenib and temsirolimus and when MDA-MB-231s were treated with sorafenib and
lapatinib. However, when treated with doxrorubicin, the IC-50s of both cell types were
similar across all platforms. These results demonstrate the utility of tailored biomaterial
systems to address basic questions related to tumor microenvironment and drug
resistance in cancer, and highlight the importance of incorporating relevant ECM factors
into drug testing.
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CHAPTER 1

INTRODUCTION

1.1 The Impact Of Cancer On Human Health
In the U.S., the Centers for Disease Control (CDC) and the National Cancer
Institute (NCI) reported more than 1 million cases of invasive cancers and more than
574,000 cancer-related deaths for each of the year between 1999 and 2011 [1]. In 2015,
the number of new cancer cases are projected to be 1.7 million with breast and prostate
cancer as the most dominant types of cancer for women and men, respectively [2]. These
two types of cancer have been the top two of cancer incidence (Figure 1.1) and are
projected to remain at the same place in 2030 [3]. Currently, the overall cost of cancer
care is projected to be $173 billion in 2020, an increase of 39% from 2010 [4]. In
addition to the high cost of cancer treatment, cancer patients usually suffer devastating
side effects from chemotherapy and radiation. Those side effects include: reduction in
bone density, cardiotoxicity, cognitive deficits, distress, fatigue, infertility, pain, and
pulmonary dysfunction [5]. Furthermore, cancer survivors usually suffer the fear of
cancer recurrence (FCR), which is a major psychological problem that results in anxiety
and depression; these psychological issues can deeply affect their quality of life and
relationships [6,7].
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Figure 1.1 Trends in incidence rates for selected cancer by sex (U.S. 1975 - 2011).
Prostate cancer has the highest incidence rate for male whereas breast cancer incidence
rate is the highest for female. Figure adapted with permission from [2]. © 2012American
cancer society, Inc.

1.2 The Biology Of Cancer
A tumor develops as a result of unregulated cell growth. Cancerous tumors are
those that are capable of metastasizing to distal tissues to form secondary tumors. A
healthy cell has to go through many stages to acquire progressive transformation to a
highly malignant cell [8,9]. This multiple step process includes the capability of
sustaining growth factor supply through autocrine or paracrine signaling, continuing to
divide indefinitely, reprogramming of cellular metabolism to sustain unlimited growth,
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being insensitive to anti-growth signals, evading apoptosis and immune destruction,
maintaining angiogenesis, invading local tissue and metastasizing to distal tissues. Two
characteristics that allow normal cells to develop these hallmark capabilities are genetic
mutations that alter many intracellular regulatory pathways and inflammation of the
tissue microenvironment that promotes tumor growth [9].
Although genetic mutation is one of the key factors for tumor development, a
single mutated gene is not enough to drive cancer cell growth. However, certain inherited
mutated genes can put a person at higher risk to develop cancers. Women who carry
BRCA1 and BRCA2 mutations have higher risks of having breast and ovarian cancers
[10]. For example, by the age of 70, the risks of having breast cancer are 71% and 84%
for BRCA1 and BRCA2 carriers, respectively [10]. However, inherited mutations in APC
and DNA mismatch repair (MMR) genes only account for 4 - 6% of colorectal cancer
(CRC) incidence in patients with family history of CRC [11]. In many cancers, multiple
mutations are required for tumor cells to acquire growth advantage, and the majority of
those are somatic mutations, which develop during a person's lifetime. For instance, the
development of CRC starts with mutations in the APC gene, which results in early
adenoma; then subsequent mutations in K-RAS, p53, SMAD4 lead to cancer [12,13].
Thousands of somatic mutations in protein kinases, which are molecular targets of many
current therapies, have been identified in many human cancers [14,15]. However, only a
portion of these mutations are considered to be 'driver' mutations, which confer growth
advantage, whereas the others are considered to be 'passenger' mutations, which do not
confer growth advantage [15].
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Besides genetic mutations, inflammation in the tissue microenvironment can give
rise to cancer development. Infection and chronic inflammation can create a
microenvironment that fosters cancer cell proliferation, survival and invasion [16]. For
instance, human papillomavirus (HPV) infection can result in oropharyngeal squamous
cell carcinomas [17], head and neck squamous cell carcinomas [18], and cervical cancer
[19]. Chronic hepatitis B or C virus (HBV or HCV) infection often leads to long-term
inflammation and development of liver fibrosis and cirrhosis [20–22] followed by
hepatocellular carcinoma [23]. Chronic infection can trigger the release of many proinflammatory cytokines/chemokines (TNF-α, TGF-β1, etc) that can recruit many immune
cells (neutrophils, monocytes, macrophages, mast cells, etc) that infiltrate the tissue in
order to fight against the infection [16]. If the infection is chronic, the long-term presence
of these cells can trigger a continuous production of cytokines, cytotoxic mediators
(reactive oxygen species or ROS), and soluble mediators of cell killing (TNF-α,
interleukins, and interferons) [16]. ROS can cause DNA damage and mutations, and
many of these chemokines can cause epigenetic alterations and promote tumor cell
growth, angiogenesis, and metastasis [16,24,25]. The presence of ROS and inflammatory
cytokines can activate local cells to modify the extracellular matrix and release many
factors that are in favor of tumor development and exacerbate the tissue inflammation
[26,27].
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1.3 Drug Resistance In Cancer
1.3.1 Adaptive drug resistance
Adaptive drug resistance is the ability of a cell to adapt to treatment after initial
exposure. Tumor cells can become resistant to drugs by increasing efflux, increasing
mutations, activating cell survival pathways, inactivating death signaling pathways,
enabling DNA-damage repair, and triggering autophagy (Figure 1.2) [28].
In order to change the rate of drug efflux, cancer cells upregulate expression of Pglycoproteins transporters that can detect and pump out cytotoxic molecules such as
doxorubicin or taxol as they cross the plasma membrane [29]. For drugs that require
receptors or transporters to enter the cells, selective resistant cells harbor mutations that
alter the function of these transporters, thus eliminating the intracellular drug uptake [29].
Kinase inhibitors have become more popular in cancer treatment due to their
lower side-effects than conventional cytotoxic chemotherapy [30]. Cancer cells can
acquire adaptive resistance to many kinase inhibitors by activating receptor tyrosine
kinases (RTKs) and their downstream signaling pathways to enhance survival. For
instance, activations of MET and AXL receptors were identified as mechanisms for
resistance to trastuzumab and lapatinib in HER2-overexpressing breast cancer cells
[31,32]. EGFR and PI3K/Akt activation promoted resistance of hepatocellular carcinoma
cells to sorafenib [33,34]. Triple-negative breast cancer cells that were treated with a
MEK inhibitor resulted in a rapid kinome reprogramming in which multiple RTKs and
downstream signaling pathways were activated to induce drug resistance [35]. In
melanoma, activation of the Akt pathway could mediate resistance to BRAF inhibitor
[36]. Squamous cancer cells can resist gefitinib, an EGFR inhibitor, by increasing
5

phosphorylation of IGFR, thus activating PI3K/Akt to enhance cell growth [37].
Moreover, cancer cells can also develop adaptive resistance to kinase inhibitors through
mutations that can change kinase binding domains, thus avoiding inhibitor binding [30].
Chronic myelogeneous leukaemia (CML) tumor cells can amplify BCR-ABL genes to
compensate for the loss of Bcr-Abl, which is inhibited by imatinib [38].
Besides increasing survival pathways, cancer cells can also regulate apoptotic
pathways through expression of anti-apoptotic molecules in Bcl-2 family such as Bcl-2
and Bcl-XL [39,40]. Loss of function of pro-apoptotic molecules such as Bax and Bak
can lead to complete resistance to the powerful chemotherapeutic drug cisplatin [41].
Overexpression of Bcl-2 and downregulation of Bax/Bak is present in many types of
cancers [42]. In addition, the epithelial-to-messenchymal (EMT) transition can trigger a
cancer-stem-cell-like phenotype and mediate drug resistance [43].
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A

B

Figure 1.2 Schematic of different mechanisms of acquired drug resistance. Cancer
cells can resist to (A) chemotherapeutic drugs that trigger DNA damages and (B) targeted
drugs that inhibit kinase activities through multiple intracellular changes. Figure adapted
with permission from [28]. © 2013 MacMillan Publishers Inc.
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1.3.2 Microenvironment-induced resistance
The tumor microenvironment is known to play an important role in providing a
niche to nurture the growth of cancer cells and mediate signals that allow them to survive
chemotherapeutic treatment [44]. Cancer cells can receive signals from the tumor
microenvironment through mechanical (ECM stiffening) and biochemical cues (Figure
1.3).

Figure 1.3 Tumor microenvironment and cancer development. The interaction
between tumor cells and the microenvironment are important in regulating cancer cells'
response to drugs. Figure adapted with permission from [45]. © 2012 Elsevier, Inc.
1.3.2.1 Extracellular matrix stiffening and cancer progression
During tumor progression, stromal fibroblasts, which differentiate into
myofibroblasts [46], and cancer-associated fibroblasts (CAF) [47], remodel the ECM by
breaking down the basement membrane and depositing fibril forming collagens [48–50].
The increase in crosslinked fibrous collagens results in tissue stiffening [50–52], which
stimulates cancer cell proliferation [52,53], invasion and intravasation [54–56], disrupts
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cell-cell adhesion [57], and alters sensitivity to growth factors [58], while simultaneously
limiting the diffusion of therapeutic agents into the tumor [59].
Mechanotransduction is the process through which cells convert mechanical
stimuli to biochemical signals that can subsequently regulate cellular function.
Mechanotransduction is mediated through integrin binding of cells to ECM proteins.
Integrins are heterodimers composed of α- and β-subunits. Different heterodimerizations
of α- and β-subunits are required when the cells bind to different ECM proteins [60].
Binding of integrins to ECM proteins can mediate many different downstream signaling
pathways such as PI3K/Akt and Ras/Raf/ERK to promote cell survival and proliferation
or Rho/ROCK to alter cell motility (Figure 1.4) [61], and integrin binding can also induce
the drug resistance of cancer cells to other chemotherapeutic drugs [62]. Expression of α6
[63], β1 [64–68], and β6 [69] are known to induced chemoresistance in breast and colon
cancers. Hence, a change in adhesive ECM proteins in the tissue microenvironment can
confer resistance to chemotherapeutics via integrin-mediated signaling. ECM stiffening
due to matrix crosslinking can induce integrin clustering, which leads to the formation of
focal adhesions [70]. There are 180 proteins associated with focal adhesions; many of
these are cytoskeletal proteins and signaling proteins such as kinases, phosphatases, and
regulators of GTPases [71]. Therefore, focal adhesions play a role as cellular
mechanosensors that transduce signals from the ECM to regulate cell behavior. The Rho
GTPase family contains many key regulators of the actin cytoskeleton. The most wellstudied members of the family are Rho, Rac1, and cdc42, which control the formation of
stress fibers, lamellipodia, and filopodia, respectively [72]. Both Rho and Rac1 are
required for the formation of focal adhesions [73]. The formation of focal adhesions can
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also activate focal adhesion kinase (FAK), which intensifies both the oncogene HER2mediated PI3K and ERK signaling pathways, to promote malignant transformation
[52,53,70]. Activated FAK also promotes 3D invasiveness and facilitates cytoskeletal
remodeling dynamics and contractile force generation [74].
Furthermore, stiffening of tumor tissue leads to the compression of blood vessels,
which limits the delivery chemotherapeutic agents and the access of immune cells to kill
tumor cells [75]. Hypoxic environments can also select for a subpopulation of cells that
can survive harsh environments, thus they tend to be resistant to chemotherapeutics and
radiation [75–77].

Figure 1.4 Representative downstream signaling pathways that can be mediated
through integrin binding. FN: Fibronectin, PI3K: Phosphoinositide 3-kinase, ILK:
Integrin-linked kinase, Pax: paxillin, MEK: Mitogen-activated protein kinase kinase,
ERK: Extracellular signal-regulated kinase, MLCK: Myosin light-chain kinase, MLC:
Myosin light chain, Cas: Crk associated substrate, RAC-1: Ras-related C3 botolinum
toxin substrate 1, PAK: p21 protein-activated kinase 1, WAVE: Wiskott-Aldrich
syndrome family protein. Figure adapted with permission from [74]. © 2013 IOP
publishing Ltd.
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1.3.2.2 Biochemical factors and cancer progression
Within tumor tissue, multiple biochemical cues, which are pre-existing or made
by tumor cells and other cell types, can mediate survival signals to tumor cells. These
biochemical cues are growth factors, cytokines, and other factors that are released from
different cell types in the tumor microenvironment. Interactions of tumor cells with these
biochemical cues are known to enhance their proliferation, survival and invasion [78–80].
Certain stromal growth factors mediate cell proliferation in the presence of
otherwise powerful chemotherapeutic drugs. For example, hepatocyte growth factor
(HGF) can impart resistance to vemurafenib in melanoma [81,82], and TGF-β can induce
the expansion of cancer stem-like cells, which are responsible for chemotherapyresistance and relapse [83]. These growth factors are generally thought to be released by
local stromal fibroblasts, which upon DNA-damage from treatments with a combination
of mitoxantrone and docetaxel or radiation, stimulate prostate cancer cell proliferation
and invasion through β-catenin signaling [84]. Cancer cells can also produce matrix
metalloproteinases (MMP) to break down the ECM, which allows them to invade the
local tissues for metastasis [85,86]. This ECM breakdown also allows cancer cells to
access to matrix-bound growth factors such as EGF and TGF-β [78].
In addition to soluble growth factors, the presence of cytokines and other cellular
secreted factors play a role in cancer cell drug resistance and invasion. The inflammatory
tumor microenvironment recruits many immune cells such as macrophages, dendritic
cells, T cells, and natural killer cells, and these infiltrated immune cells are the major
source of cytokine production [87]. Some cytokines have an anti-tumor effect whereas
some promote tumor development [24,88]. Interleukin 8 (IL-8) is known to mediate
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breast cancer cell migration and invasion [89,90]. IL-8 and VEGF autocrine signaling can
induce EMT, which results in drug resistance, and invasiveness [91]. IL-6, IL-17, and IL23 are also known to enhance tumor progression [24]. IL-4 was also found to mediate
drug resistance in colon cancer stem cells [92]. Tumors grown from drug resistant cells,
which had characteristics of cancer stem cells, were found to have elevated levels of
cytokines, angiogenic and growth factors such as VEGF, bFGF, IL-6, IL-8, HGF, PDGFBB, G-CSF, and SCGF-β [93].

1.4 Biomaterial Platforms For Cancer Studies
1.4.1 The cost of drug development
Part of the incredible cost of cancer care is due to the high price tag of cancer
drugs. It costs over $1 billion to bring a new drug to the market, and the success rate is
approximately 10% [94]. The major reason for this low overall success rate and
unimaginable cost is due to the limitation of preclinical cancer models, which are not
predictive of human outcomes [94]. Typically, a drug development process will start with
the identification of a biologically relevant target that drives the disease progression, then
followed by a high-throughput screening of many small molecules or biologics. The
molecules that emerge from the high-throughput screening are further optimized and
tested on relevant animal models before entering clinical trials. However, many
compounds that show efficacy during high-throughput screening do not show similar
results when subsequently tested in vivo on animals or humans. This highly inefficient in
vitro high-throughput screening increases not only the cost but also the drug development
time, which is approximately 14 years on average (Figure 1.5) [95]. Currently, the high12

throughput screening is usually performed with cells on plastic plates. Given the
important roles of the ECM's mechanochemical signals in regulating cancer cell growth
and their drug response as discussed earlier, it is critical to have an in vitro, highthroughput biomaterial drug- testing platform that can capture these relevant
mechanochemical cues.

Figure 1.5 An outline of the standard drug development pipeline. Figure adapted with
permission from [95]. © 2004 MacMillan Publishers Inc.
1.4.2 Hydrogels for mimicking tumor microenvironment
Hydrogels are porous hydrophilic materials. Due to their hydrophilicity and
biocompatibility, hydrogels are widely used for many biomedical applications from drug
delivery to tissue engineering [96], such as how cell and matrix interaction governs stem
cell fate on 2D [97] and in 3D [98]. In addition, hydrogels have been used as platforms
to study many biological phenomena in human diseases, such as cell migration [99] in 2D
[100–102] and 3D [103–105], cellular response to drug treatment in ovarian cancer [106]
and melanoma [107].
Hydrogels are typically derived from natural or synthetic polymers. Common
natural polymers include hyaluronic acid, chitosan, collagen, fibrin, agarose, alginate
[108]. Some of the natural polymers such as collagen, fibrin, and hyaluronic acid are
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components of mammalian ECM, thus they also contain many integrin binding sites for
cell adhesion. On the other hand, chitosan, alginate, and agarose are polysaccharidesderived from other natural sources (algae, chitin, etc), and they do not contain integrin
binding sites. Natural polymers can be physically crosslinked to form hydrogels.
Depending on the type of polymer, different methods can be utilized to induce physical
crosslinking such as warming/cooling the polymer solution, mixing polyanion with
polycation or with mutivalent ions of opposite charge, and changing pH [96]. However,
hydrogels formed from these natural polymers are degradable over time through different
mechanisms [108], and it is not possible to independently control the amount of binding
sites and the material mechanical property. Increasing or decreasing the number of
adhesive sites also increases or decreases the mechanical stiffness since the mechanical
properties of these hydrogel are dependent on protein concentration. Therefore, some
groups have spurred the development of natural- polymer hydrogels that allow
independent control of binding sites and mechanical property. For example, hyaluronic
acid can be modified with methacrylate and maleimide functional groups, and these
functional groups can be chemically crosslinked by DL-dithiothreoitol (DTT) or Ultra
Violet radiation [109,110].
In contrast, synthetic polymer hydrogels allow independent control over
mechanical and adhesive properties. Synthetic hydrogels are derived from derivatives of
synthetic polymers such as poly(hydroxyethyl methacrylate) (PHEMA), poly- (ethylene
glycol) (PEG), poly(vinyl alcohol) (PVA), poly(ethylene oxide) (PEO), polyacrylamide
(PAAm), etc [108]. Polymerization methods include chain-growth polymerization
through free-radical polymerization and step-growth polymerization through Michael-
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addition reactions [111]. Since synthetic polymers do not contain cell binding sites like
natural polymers, peptides or full-length proteins that mediate cell adhesion need to be
incorporated into the gels. Therefore, the mechanical properties can be modified through
changing of polymer concentration or cross-link density without affecting the number of
cell binding site. Hydrogel surfaces can be functionalized with cell binding peptides or
full-length proteins following different bioconjugate methods such as azide-alkyne
"click" chemistry [112]. In three dimensions, both cell binding peptides or degradable
peptides can be incorporated into the hydrogel system [111,113,114]. Therefore, the
ability to incorporate specific binding or degradable peptides in a controllable manner
allows synthetic hydrogel to be tailored for a specific study. For example, both RGD cell
binding peptide and MMP-degradable crosslinkers were incorporated into 3D hydrogel
systems to study how matrix stiffness affects the progression of glioblastoma [115], and
an in situ fluorogenic MMP sensor peptide was used to investigate how drug treatment
influences MMP activity of metastatic melanoma cells in three dimensions [116]. RGD is
the binding site of fibronectin, and many other cell binding peptides from other proteins
are also identified [62].
In addition, composite hydrogels that are made from both natural and synthetic
polymers have been used in many studies. For instance, composite hydrogels of PEG and
collagen were used as scaffolds for immune cells [117] and pancreatic cancer cells [118].
Hybrid PEG-based hydrogels can also be created by combining PEG polymers with the
recombinant proteins containing both fibrinogen and collagen binding sites [119].
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1.5 Hypothesis
As depicted in Figure 1.3, the tumor microenvironment plays an important role in
promoting the growth of cancer cells and mediating resistance to chemotherapeutics. The
change in the ECM properties during disease progression results in mechanical and
biochemical changes that profoundly affect cell behaviors via alterations in intracellular
signaling (Figure 1.4). Since many novel targeted drugs have been designed to inhibit
specific intracellular pathways as a mechanism to stop cancer cell growth, it is not well
understood how both mechanical and biochemical changes can lead to alterations in
downstream intracellular signaling pathways that ultimately hamper the effectiveness of
targeted drugs. I hypothesize that cancer cells become resistant to chemotherapeutics
via interaction with the physicochemical cues from the tumor ECM (Figure 1.6). The
research presented in this dissertation aims to elucidate the mechanisms by which the
tumor ECM contributes to drug resistance in both 2D and 3D. Testing this hypothesis
requires the development of a high-throughput platform, which can capture the ECM
mechanochemical properties, to facilitate the drug screening process. These 2D and 3D
platforms were made with synthetic hydrogels that allow tunable mechanical properties
and easy functionalization of full-length ECM proteins or short peptides that contain
binding sites found in natural ECM proteins. Anti-cancer drugs were tested with cells
seeded on the hydrogel surface or encapsulated within the hydrogels. Furthermore, the
intracellular signaling that is mediated by the interactions with these 2D and 3D
platforms were examined.
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Dead or Alive?

Figure 1.6 An outline of governing hypothesis.

1.6 Objectives For Dissertation
I hypothesize that the mechanical and biochemical properties of the ECM can
influence cancer cell response to chemotherapeutics. The research presented in this
dissertation were outlined as specific aims in Figure 1.7.
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Hypothesis
Mechanochemical properties of
the ECM regulate cancer cell
response to chemotherapeutics

Aim 1: Design novel
biomaterial for mechanobiology
on 2D

Aim 4: Design novel
biomaterial platforms for 3D
culture of cancer cells

Aim 2: Design novel 2D high
through-put platforms

Aim 5: Examine cellular
response to drugs across
multiple types of platform

Aim 3: Study cellular response
to drugs on varying material
stiffness and cell-binding
conditions

Figure 1.7 Objectives for Dissertation. Chapter 2 describes aim 1, where the novel
PEG-PC biomaterial was created for mechanobiology. Chapter 3 describes aim 2, where
high-throughput platforms were designed from PEG, PEG-PC, and PAA, and cell
response to drug was examined as a function of integrin binding. Chapter 4 describes aim
3, where cancer cell response to sorafenib was studied across varying conditions. Finally,
chapter 4 describes aims 4 and 5, where both PNIPAAm-PEG and PEG-MAL were used
as platforms for 3D culture, and cell response to drug was studied with different
platforms.
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1.7 Significance
The mechanical and biochemical cues from the ECM regulate many cellular
behaviors including proliferation, differentiation, and migration. However, how these
physicochemical cues together affect cell response to chemotherapeutics is not well
understood. The research presented in this dissertation addresses this question at the subcellular level across varying geometries, material properties, and cell-binding ligands.
Insights gained from this research will not only provide better understanding of cellmatrix and drug interactions, but also aid in future design of biomaterials to study many
other diseases. The novel PEG-PC gel developed from this research has a mechanical
range that matches or exceeds any previously reported hydrogel system and can be served
as an ideal platform for future studies in regenerative medicine and disease mechanisms.
The high-throughput biomaterial platforms created from this research are promising
predictive tools for future drug screening, and help to facilitate the process of drug
development.
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CHAPTER 2

SYNTHESIS OF PEG-PC BIOMATERIAL SYSTEM AND
MECHANICAL/STRUCTURAL CHARACTERIZATION

2.1 Abstract
Both synthetic and natural biomaterial platforms are commonly used as mimics of
in vivo tissues for in vitro studies in mechanobiology. These biomaterial platforms can be
tailored to capture many aspects of the in vivo ECM, therefore studies conducted using
these platforms are potentially more predictive of in vivo outcomes than traditional tissue
culture plastic plates. Synthetic biomaterials allow the mechanical and adhesive
properties to be tuned independently, as opposed to natural biomaterials. In response to
the needs of new synthetic biomaterials with improved properties, a new class of
hydrogels was created by combing PEG and phosphorylcholine (PC). The resulting
hydrogels have an extremely wide range of tunable mechanical properties, with small
mesh sizes and high optical transparency. As a proof of concept, the stiffness sensing of
multiple cell lines on the hydrogels was studied through quantification of focal adhesion
properties. This novel PEG-PC biomaterial can be useful for many applications in
studying mechanobiology.
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2.2 Introduction
Both naturally derived polymers and chemically synthetic polymers are widely
used as biomaterial platforms to support cell culture in two and three dimensions (2D,
3D). The two most common naturally derived materials are collagens and matrigel. Both
of these materials contain native binding sites for cell adhesion; however, it is not
possible to independently control the amount of binding sites and the material mechanical
property, i.e. increasing or decreasing the number of adhesive sites also increases or
decreases the mechanical stiffness. On the other hand, synthetic polymer hydrogels allow
independent control over mechanical and adhesive properties. The two most commonly
used synthetic hydrogels are made from either polyacrylamide (PAA) or poly(ethylene
glycol) (PEG) polymers. The PAA hydrogel was the first popularized biomaterial used in
mechanobiology studies. However, these gels have limited mechanical range and are not
suitable for three-dimensional (3D) studies. PEG-based hydrogels have a modulus of 20500 kPa [1,2], and can be engineered to contain specific hydrolytic [3,4] or enzymatic
degradable sites [5] for 3D cell culture. Both PEG and PAA can be coupled with short
peptides or full-length proteins of interest.
Phosphorylcholine is a zwitterion that locates at the outer membrane of the cells,
providing an inert surface for many biological reactions [6]. 2-methacryloyloxyethyl
phosphorylcholine (MPC) is a monomer containing a phospholipid polar group. Copolymers that incorporated MPC were shown to suppress clot formation and reduce
platelet adhesion due to its anti-protein adsorption property, which is a result of
enhancing surface hydrophilicity [7]. MPC co-polymers were also shown to be more antiprotein adsorptive than poly[2-hydroxyethyl methacrylate (HEMA)] due to larger free
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water fraction on the surface [7]. Therefore, inclusion of a PC zwitterion group into a
PEG hydrogel can potentially create a more hydrophilic biomaterial and prevent the
proteins from culture serum to passively adsorb to the hydrogel surface and influence cell
behavior.
Ishihara and co-workers investigated the mechanical property of MPC polymer
hydrogels, which were cross-linked either with N,N'- methylenebisacrylamide (BIS) or
2-(methacryloyloxy)ethyl-[N-(2-methacryloyloxy)ethyl]phosphorylcholine (MMPC).
They found that MMPC showed higher cross-linking reactivity with MPC than BIS,
therefore improving the tensile property of the material [8]. This result suggests that
incorporation of PC groups into a hydrogel network can potentially increase the
mechanical properties. MPC monomers can be incorporated into a hydrogel network
following free-radical polymerization [9] or Michael addition [10]. The work in this
chapter describes the creation of a novel "PEG-PC" hydrogel by co-polymerizing MPC
with PEG dimethacrylate (PEGDMA) following free-radical polymerization. The
resulting PEG-PC hydrogels have a mechanical range that spans four orders of magnitude
(1-10,000 kPa), which matches or exceeds any previously reported hydrogel system, and
have an improved anti-protein adsorption property compared to PEGDMA hydrogels [9].
Here, the bulk mechanical properties of PEG-PC hydrogels are measured using a
compression test in which the hydrogels, in the absence of cells, are deformed at a
constant strain rate.
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2.3 Materials And Methods
2.3.1 PEG-PC hydrogel formation
2-methacryloyloxyethyl phosphorylcholine (Sigma-Aldrich) (MPC) was
dissolved in phosphate buffered saline (PBS) to make a final concentration of 0.6 M (17
wt %). PEGDMA (average Mn 750, Sigma-Aldrich, St. Louis, MO), varied between final
concentrations of 7.4 mM and 0.7 M (0.5−55 wt %), was added into the MPC solution to
create various PEG-PC polymer hydrogel precursor solutions. Solutions were degassed
for 30 s with nitrogen and sterilized using a 0.2 μm syringe filter (Thermo Fisher
Scientific, Waltham, MA). Depending on the desired format, two different free radical
initiators were used for polymerization. To cure under UV light, 0.8 wt % Irgacure 2959
(BASF, Ludwigshafen, Germany) was added, and gel formation was induced with a
Spectroline High-Intensity UV Lamp at 365 nm (Model no. SB-100P, Westbury, NY),
3.5 in. from the gel for 7 min. To form hydrogels in the absence of UV light, 0.05 wt %
ammonium persulfate (APS) and 0.125 vol % tetramethylethylenediamine (TEMED,
Bio-Rad Laboratories, Hercules, CA) were added, and gels were polymerized under
nitrogen for 10 min.
2.3.2 Hydrogel mechanical and structural characterization
PEG-PC hydrogel cylinders for mechanical compression testing were formed in
5-mm Teflon molds and swelled in PBS for 48 h. Post swelling, hydrogel dimensions
were measured with digital calipers, and mechanical compression tests were performed
with a TA Instruments (New Castle, DE) AR-2000 rheometer at a 2 μm/s strain rate. The
Young’s modulus (E) for each hydrogel was calculated by plotting the measured normal
force between 0 and 4% strain and dividing the slope of the best-fit linear regression by
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the hydrogel cross-sectional area. The Young’s modulus was obtained for 4 or more
hydrogels for each PEGDMA concentration. To determine an approximate average mesh
size as a function of PEGDMA cross-linker content with constant PC content, hydrogels
were swelled in PBS for 48 h, then weighed, fully lyophilized, and weighed again. The
average mesh size, ξ, of the PEG-PC hydrogels was determined as a function of
PEGDMA cross-linker concentration according to the Flory theory as modified by Canal
and Peppas:
−

1
3

𝜉 = υ2,s (r̅ 2 )1/2

where 𝜐2,𝑠 is the swollen volume fraction of polymer and (r̅ 2 )1/2 is the average end-toend distance of the PEGDMA cross-linker.

2.3.3 Making gels on coverslips and protein functionalization
18 mm glass coverslips (Thermo Fisher Scientiﬁc, Waltham, MA) were plasma
treated (Harrick Plasma, Ithaca, NY) and subsequently methacrylate-silanized with 2
vol% 3-(trimethoxysilyl) propyl methacrylate (Sigma-Aldrich, St. Louis, MO) in 95%
ethanol (adjusted to pH 5.0 with glacial acetic acid) for 5 min, washed 3 times with 100%
ethanol, and dried at 120 °C for 15 min. To make thin PEG-PC hydrogels with even
heights and suitable for microscopy, 80 μL PEG-PC hydrogels were polymerized with
APS and TEMED between a methacrylated-silanized coverslip and an untreated coverslip
for 20 min on the bench. After polymerization, the hydrogels were allowed to swell in
PBS, and the non-treated coverslips were removed easily with fine forceps.
The gel surfaces can be coupled with the heterobifunctional cross-linker, which
contains a highly amine-reactive functional group for covalent linkage to a variety of
integrin-binding proteins. Two heterobifunctional cross-linkers used were sulfo41

SANPAH (ProteoChem, Denver, CO) and acrylate-poly(ethylene glycol)-succinimidyl
valerate (PEG-SVA; Laysan Bio, Arab, AL). With sulfo-SANPAH, swollen gels on
coverslips were transferred to 12-well tissue culture dishes and treated with sulfoSANPAH (0.3 mg/mL in pH 8.5 HEPES buffer) under UV light for 15 min, rinsed twice
with HEPES buffer, and followed immediately by incubation with proteins overnight.
With PEG-SVA, the cross-linker was added to the PEG-PC prehydrogel solution at 0.11
wt %. This method incorporates an amine reactive group into the bulk of the hydrogel
instead of isolating the reaction at the surface like sulfo-SANPAH. The protein used was
type I collagen (rat tail, Life Technologies), recombinant human collagen III (FibroGen,
San Francisco, CA), and human plasma fibronectin (EMD Millipore, Billerica, MA).
Protein solution was made in sterile PBS and adjusted to pH 3 to prevent collagen
gelation. Post protein reaction, hydrogels were washed 3 times with sterile PBS with
shaking and then UV sterilized for 60 min before cell seeding.
2.3.4 Cell culture
All supplies were purchased from Life Technologies (Carlsbad, CA) unless
otherwise noted. Human breast cancer cell lines (MDA-MB-231 and SkBr3) were
generous gifts from Dr. Shannon Hughes at the Massachusetts Institute of Technology,
and were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) at 37ºC and 5%
CO2. Human hepatocellular carcinoma (HCC) cells (HEP3Bs, American Type Culture
Collection, Manassas, VA) were cultured in modified Eagle's medium (MEM)
supplemented with 10% FBS and 1% P/S at 37ºC and 5% CO2. Human aortic smooth
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muscle cells (HASMCs) were cultured in DMEM supplemented with 1% P/S and smooth
muscle growth supplement (SMGS).
2.3.5 Immunofluorescent imaging and focal adhesion quantification
Hydrogels with Young's moduli of 18, 26, 165, and 400 kPa were made and
subsequently coupled with 10 μg/cm2 collagen I. Cells were seeded at a density of 10,000
cells/cm2 in serum-free medium and allowed to adhere for 48 hours. Cells were rinsed
two times with warm PBS, fixed with 4% formaldehyde, permeabilized with Trisbuffered saline (TBS) containing 0.5% Triton X-100 (Promega), and blocked with AbDil
(2 wt.% BSA in TBS with 0.1% Triton X-100, TBS-T). F-actin was labeled with Alexa
Fluor 555-conjugated phalloidin for 1 h. Vinculin was labeled with a monoclonal mouse
anti-vinculin antibody (Sigma-Aldrich) for 1 h, followed by an anti-mouse FITC
secondary antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 h.
Cell nuclei were labeled with DAPI (MP Biomedicals, Santa Ana, CA) for 5 min. Cells
were thoroughly washed between labeling steps with TBS-T. Each sample was treated
with ProLong Gold antifade reagent for 5 min before imaging on a Zeiss Axio Observer
Z1 microscope with a 63x oil immersion objective (Carl Zeiss AG, Oberkochen,
Germany), and images were compiled in ImageJ (NIH, Bethesda, MD).
2.3.6 Quantification of protein adsorption
A modified ELISA [11] was used to quantify non-specific protein adsorption.
The fully swollen hydrogels were incubated with 10 mg/mL bovine serum albumin
(BSA; Sigma) for 20 h at 37 °C. The gels were subsequently incubated with a primary
antibody to BSA (Life Technologies) and a secondary antibody conjugated to horseradish
peroxidase (HRP; Abcam, Cambridge, U.K.) in PBS for 90 min. The gels were washed 5

43

times with PBS between each incubation. The gels were then incubated with 0.1 mg/mL
3,3′,5,5′-tetramethylbenzidine (TMB; Sigma) and 0.06% hydrogen peroxide (Fisher) in
0.1 M sodium acetate (pH 5.5; Sigma) for 1 h at room temperature with shaking. Then an
equal volume of 1 M sulfuric acid (Sigma) was added, and the absorbance at 450 nm was
measured with a ELx800 absorbance microplate reader (BioTek).
2.3.7 Statistical Analysis
Statistical analysis was performed using Prism v5.04 (GraphPad Software, La
Jolla, CA). Statistical significance was evaluated by either using unpaired Student’s t
tests (with Welch’s correction as necessary) or one-way analysis of variance (ANOVA)
with a Tukey post-test. Data are reported as mean ± standard deviation. p ≤ 0.05 is
denoted with *, ≤ 0.01 with **, and ≤ 0.001 with ***; P > 0.05 is considered not
significant (“ns”).

2.4 Results
2.4.1 PEG-PC hydrogels have a wide range of Young's Moduli
PEG-PC hydrogels were synthesized by combining various concentration of
PEGDMA with 0.6M PC (17 wt %) followed by free-radical polymerization (Figure 2.1).
The photopolymerized PEG-PC hydrogels have a tunable mechanical range over 4 orders
of magnitude of Young's moduli, from 0.9 ± 0.2 kPa at 7.4 mM (0.5 wt %) PEGDMA to
9300 ± 900 kPa at 0.7 M (55 wt %) PEGDMA (Figure 2.2).
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Figure 2.1 Schematic of PEG-PC hydrogel structure. PEG-PC hydrogels were
prepared by addition of PEGDMA and PC followed by free-radical polymerization. At
low PEGDMA concentrations, the network structure is dominated by PEGDMA-crosslinked linear PC polymers, whereas the network structure is dominated by PEGDMA
with sparsely distributed PC groups at very high PEGDMA concentrations. Figure
adapted with permission from [9]. © 2013 American Chemical Society.

When APS and TEMED are used as initiators for polymerization, there were
minor differences in Young's modulus compared to using Irgacure for the same
PEGDMA concentration (Figure 2.3A). This trend was consistent at low concentrations
of PEGDMA. When comparing the gel fractions between the two polymerization
methods, polymerizing with Irgacure is less efficient, and the resulting gels had larger
mesh sizes and were softer (Figure 2.3B).
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Figure 2.2 Young's modulus of PEG-PC. Young’s modulus, E, of PEG-PC hydrogels
as a function of PEG cross-linker concentration from 7.4 mM to 0.7 M. PC was held at 17
wt % (0.6 M). Error bars are standard deviations. Each adjacent pair is significantly
different as determined by an unpaired Student’s t test with p < 0.001 or better. Figure
adapted with permission from [9]. © 2013 American Chemical Society.
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Figure 2.3 The mesh sizes and Young's modulus of PEG-PC following
polymerization with Irgacure and APS/TEMED. The mesh sizes and Young's
modulus varies between two different methods of polymerization, Irgarcure and
APS/TEMED, at low PEGDMA concentrations. (A) Young's modulus of hydrogels
polymerized with APS/TEMED are much higher compared to polymerization with
Irgacure at low PEGDMA concentrations. (B) Hydrogels polymerized with APS/TEMED
have smaller mesh sizes and higher percentage of polymerization. Figure adapted with
permission from [9]. © 2013 American Chemical Society.
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2.4.2 PEG-PC have small mesh sizes and structural dependent swelling
When the amount of PEGDMA cross-linker increases from 7.4 mM to 0.7 M, the
mesh size decreases from 5.3 ± 0.4 nm to 0.95 ± 0.01 nm (Figure 2.4). However, the
expected strong correlation between mesh size and Young’s modulus was found only
over a partial range of cross-linker concentrations: from 7.4 to 135 mM PEGDMA
(Pearson’s R = −0.8383, p < 0.05) and from 0.3 to 0.7 M PEGDMA (Pearson’s R =
−0.9572, p < 0.05). Interestingly, these behaviors separate where the weight percent of
PC and PEGDMA are equal in the gel. This finding suggests a hydrogel structural
change, from one dominated by methacrylic PC polymer that is cross-linked by
PEGDMA to one dominated by a PEG polymer, which is also cross-linked by PEGDMA,
with PC pendant groups (Figure 2.1). The percentage of PBS uptake was calculated from
the masses of the fully swollen hydrogels and pre-swelling hydrogels (right after
polymerization). Due to the hydrophilicity of the PC groups, PEG-PC can swell in PBS
at all cross-linker concentrations, and there are also two different swelling regimes that
are separated at the point where the hydrogel structural change occurs (Figure 2.5).
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Figure 2.4 The average mesh sizes of PEG-PC hydrogels (PC at 0.6 M) as a function
of PEG cross-linker concentration. Error bars are standard deviations (N ≥ 4). Figure
adapted with permission from [9]. © 2013 American Chemical Society.
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Figure 2.5 PEG-PC swelling behavior. PEG-PC swelling behavior in PBS, which is
maintained at even very high cross-linker concentrations. Figure adapted with permission
from [9]. © 2013 American Chemical Society.
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2.4.3 PC groups reduce non-specific adsorption of proteins to PEG gel
Collagen I, which was covalently coupled to the hydrogel surface by using sulfoSANPAH, was detected by immunofluorescence, whereas no collagen I was detected on
gel surfaces without the use of sulfo-SANPAH (Figure 2.6). These results demonstrate
qualitatively that PEG-PC hydrogels are non-fouling to protein adsorption. To determine
quantitatively whether incorporation of the hydrophilic PC groups enhanced resistance to
protein adsorption to PEGDMA, bovine serum albumin (BSA) was allowed to adsorb to
the surface of PEGDMA only (0.145 M) and PEG-PC (0.6 M PC and 0.054 M
PEGDMA) hydrogels that had the same Young's modulus, and an ELISA was performed.
There was a small amount of BSA detected on PEGDMA hydrogel surface, but not with
the PEG-PC hydrogel (Figure 2.7A). When the PEGDMA concentration was kept
constant at 0.084 M whereas PC was varied from 0.15 to 0.6 M, the BSA adsorption
decreased with increasing PC content (Figure 2.7B).
With sulfo-SANPAH

Without sulfo-SANPAH

Figure 2.6 Proteins can be coupled to PEG-PC surface in a controllable manner.
Collagen I is covalently coupled to the gel surface by using sulfo-SANPAH.
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Figure 2.7 PEG-PC hydrogels are non-fouling. (A) No BSA was detected on the PEGPC hydrogels compared to PEGDMA hydrogels that have similar modulus. (B) Adsorbed
BSA at a constant PEGDMA concentration decreases with increasing PC content,
demonstrating the ability of PC to prevent fouling. Figure adapted with permission from
[9]. © 2013 American Chemical Society.

2.4.4 PEG-PC hydrogels are suitable for mechanobiology studying of various cell
types
PEG-PC hydrogels were polymerized and covalently attached on glass coverslips.
Integrin-binding ECM proteins were covalently coupled to the hydrogel surface in order
to induce cell adhesion and spreading (Figure 2.8). The two methods used to couple ECM
proteins were sulfo-SANPAH and PEG-SVA (Figure 2.9). When neither of the
heterobifunctional cross-linker was used, a minimal cell attachment and spreading was
observed as indicated in Figure 2.9A with HASMCs (bottom left) and HEP3Bs (bottom
right). This result demonstrates that PEG-PC hydrogels are non-fouling, resistant to nonspecific cell attachment, and useful for studies in which parsing the roles of integrinbinding versus mechanical properties is desired. Many different cell types can also attach
and spread out on PEG-PC gels with different stiffnesses (Figure 2.10).
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Figure 2.8 Schematic of cell attachment to PEG-PC hydrogel via integrin binding.

Figure 2.9 Cell adhesion can be controlled through protein coupling. (Left) HASMCs
on PEG-PC (170 kPa) with (top) or without (bottom) sulfo-SANPAH and collagen I at 10
μg/cm2; scale bar is 100 μm. (Right) HEP3B cells on PEG-PC (8.3 kPa) with (top) or
without (bottom) PEG-succinimidyl valerate (PEG-SVA) and 65% collagen III, 23%
collagen I, and 2% fibronectin at 5 μg/cm2; scale bar is 200 μm. Figure adapted with
permission from [9]. © 2013 American Chemical Society.
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Figure 2.10 Modulus and integrin-binding on PEG-PC gels controls cell morphology. (i, ii) HASMCs on PEG-PC (compliant = 3
and stiff = 170 kPa, respectively, except for SkBr3 for which stiff = 400 kPa) with collagen I. Vinculin = green, F-actin = red, and
Nucleus = blue. (iii, iv) HEP3Bs. (v, vi) MDA-MB-231s. (vii, viii) SkBr3s. Scale bar is 20 μm. Figure adapted with permission from
[9]. © 2013 American Chemical Society.
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Figure 2.11 Image thresholding and focal adhesion tracing. Image thresholding and
focal adhesion tracing (labeled vinculin) were performed in ImageJ. Figure adapted with
permission from [9]. © 2013 American Chemical Society.
In order to demonstrate that cells sense differences in the stiffness of PEG-PC
hydrogels, the number of focal adhesions, their areas, and shapes were quantified. Liver
cancer (HEP3B) and two breast cancer cell lines (SkBr3 and MDA-MB-231) were
cultured for 48 h on PEG-PC gels of varying stiffness, coupled with 10 μg/cm2 collagen
I. The cells were then fixed and stained for vinculin, which co-localizes with focal
adhesions. ImageJ was used to quantify the focal adhesions (Figure 2.11). HEP3Bs had
significantly fewer focal adhesions per cell on the 165 and 400 kPa gels compared the 18
kPa gels, whereas the amount of focal adhesions of the other cell lines did not show any
significant difference with respect to stiffness (Figure 2.12A). Focal adhesion area
decreased with Young’s modulus in SkBr3 and 231 cells (areas on the stiffest PEG-PC
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were reduced approximately 37% and 45% from the softer PEG-PC hydrogels, p < 0.05
and p < 0.01, respectively), and interestingly, HEP3B focal adhesion area is biphasic
(area on 26 kPa PEG-PC is 65% larger than on 18 and 165 kPa, p < 0.01) (Figure 2.12B).
SkBr3 was the only cell line that had focal adhesion elongation decreases with increasing
stiffness (Figure 2.12C). These results demonstrate the ability of PEG-PC hydrogel
mechanical properties to tune cytoskeletal organization and reveal that
mechanosensitivity is cell line specific. The proliferation of these cell lines on the same
stiffnesses and the Spearman correlation between the proliferation and focal adhesion
were also quantified. There was not any correlation between proliferation and focal
adhesion area or elongation (Figure 2.13).
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Figure 2.12 Focal adhesion characterization. PEG-PC modulus control of focal
adhesions is cell-specific. Average number of focal adhesions (FA) counted per cell (A),
average focal adhesion area (B), and average focal adhesion elongation (C) as a function
of PEG-PC modulus. Figure adapted with permission from [9]. © 2013 American
Chemical Society.
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2.5 Discussion
With 17 wt % (0.6 M) of PC, polymerization of PEG-PC hydrogels can be
achieved with the amount of PEGDMA cross-linker as low as 7.4 mM, which results in
0.9 kpa hydrogels, and the hydrogel stiffness can be expanded up to 9,300 kPa at 0.7 M
of PEGDMA (Figure 2.14). PEG-PC hydrogels can also be polymerized with lower
concentrations of PC combined with higher concentrations of PEGDMA such as with
13.5 wt % PC (Figure 2.15) and 8 wt % PC (Figure 2.16). However, the hydrogels only
remain transparent with an addition of PEGDMA cross-linker up to 0.3 M, whereas
PEGDMA only hydrogels are opaque at low PEGDMA and become more transparent as
the cross-linker concentration increases (Figure 2.17).

Figure 2.14 Young's modulus of PEG-PC. Increasing the PEGDMA also increases the
Young's Modulus. The PC content was held at 17 wt. % (0.6 M). Figure adapted with
permission from [9]. © 2013 American Chemical Society.
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Figure 2.15 Young's modulus of PEG-PC at 0.5 M PC. Young’s modulus, E, of PEGPC hydrogels as a function of PEG cross-linker concentration from 108 mM to 133 mM.
PC was held at 13.5 wt. % (0.5 M). Error bars are standard deviations.
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Figure 2.16 Young's modulus of PEG-PC at 0.3 M PC. Young’s modulus, E, of PEGPC hydrogels as a function of PEG cross-linker concentration from 83 mM to 179 mM.
PC was held at 7.6 wt. % (0.3 M). Error bars are standard deviations.

Figure 2.17 Images of PEG-PC hydrogels. PEG-PC hydrogels are optically transparent
at low PEGDMA concentrations. The concentrations shown are of PEGDMA. PEG-PC
hydrogels are 0.6 M PC. Figure adapted with permission from [9]. © 2013 American
Chemical Society.
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The range of stiffness of PEG-PC hydrogels is much wider than PEGDMA only
hydrogels, and it covers the stiffness of many tissue types such as liver (5-55 kPa) [12–
14], breast tumors (134-166 kPa) [15], articular cartilage (950 kPa), spinal cord (89 kPa),
thyroid (9 kPa) [16]. PEGDMA hydrogels cannot polymerize at concentrations less than
70 mM (5 wt %), limiting the range of moduli obtainable. Incorporation of the PC
polymer allows polymerization with as low as 7.4 mM PEGDMA (0.5wt %). This is
likely due to the overall increase in polymer mass contributed from the PC. The 135 mM
cross-linker hydrogels had mesh sizes half that of a 135 mM PEGDMA gel without PC,
whereas the Young’s modulus is nearly 10 times higher [17], implying the inherent
structural changes when PC is incorporated. At concentrations of PEGDMA above 135
mM, there was a regime change within the hydrogel from a PC-domintated structure to a
PEG-dominated structure. The changes in Young's modulus and mesh size are less
dependent on cross-linker concentration as opposed to lower PEGDMA regime.
However, the swelling behavior in this regime is still largely dependent on PEGDMA
concentrations. Overall, the ability of PEG-PC to form two very different polymer
structures may explain for its impressive mechanical range.
PEG-PC hydrogels allow independent tunability of stiffness and ligand density
and have enhanced hydrophilicity for reduction of nonspecific protein adsorption while
maintaining high optical clarity for modern quantitative microscopy techniques. PEG is a
well characterized amphiphilic polymer, and PEG-based hydrogels are widely used in
many biological applications due to its biocompatibility. PC molecules contain
phospholipid groups, which are major components of biological membrane. Thus,
combining PC and PEG to make PEG-PC results in highly biocompatible hydrogels. In
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their studies, Ishihara et al. suggests that the state of water molecule around PC polymers
is different from that of general amphiphilic polymers [7]. PC-incorporated polymers
have large amount of free water in hydrated state, which is similar to the state water in
aqueous solution. Thus, when a protein molecule in aqueous solution is in contact with
the polymer surface, it does not need to release bound water molecules. This phenomena
prevents the hyrophobic interactions between the protein molecule and the hydrophobic
part of the polymer, which is a mechanism for protein adsorption. Protein molecules can
contact PC-incorporated polymers reversibly without going through an irreversible
conformational change in structure, which allows exposure of hydrophobic domains,
leading to hydrophobic interactions [7]. This unique property of the PC groups imparts a
highly anti-protein adsorption characteristic to PEG-PC hydrogels. Furthermore, PEG-PC
hydrogels were experimentally shown to be more resistant to BSA adsorption compared
to PEGDMA hydrogels of the same modulus, and the amount of adsorbed protein is
inversely related to the PC content of the hydrogel (Figure 2.7). These results further
confirm the non-fouling properties of PC. Another hydrophilic hydrogel system widely
used is derived from hyaluronic acid [18–20]. However, hyaluronic acid can have
bioactivity through interaction with CD44 receptors in certain cell types [18,20]. Thus,
PC has the advantage of being biocompatible without interfering with cell behavior.
When HASMC, HEP3B, SkBr3, and MDA-MB-231 cell lines were cultured on
PEG-PC gels from 18 to 400 kPa Young's moduli functionalized with collagen I, their
focal adhesion properties corresponding to substrate modulus were cell-type dependent.
These cell types originate from tissues that have different stiffnesses; thus their stiffness
sensing can be different among cell type. Besides, the mechanotransduction machinery
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depends on many factors such as integrins, proteins that make up adhesion complexes,
proteins that regulate actin assembly at adhesion sites, and many more. For example, β1
integrin is a major integrin that binds to collagen I [21], and SkBr3 cells inherently have
lower β1 intergin expression compared to MDA-MB-231 [22]. This partially helps to
explain some observed differences in their focal adhesion properties between these two
cell lines.

2.6 Conclusions
A new biomaterial platform, PEG-PC, was developed through copolymerization
of PEGDMA polymers and PC monomers. This novel biomaterial has a much wider
range of Young's modulus and more anti-adsorptive to non-specific protein bindings than
PEGDMA hydrogels. Its impressive mechanical properties, which can be tuned over four
orders of magnitude in Young's modulus, make it an ideal platform for
mechanotransduction studies. It was demonstrated that different cell types can be cultured
on PEG-PC surfaces and can sense different stiffnesses. In addition, PEG-PC is
inexpensive and easy to synthesize, and these advantages will make it feasible for other
labs to apply this system in their studies of cellular responses to ECM modulus.
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CHAPTER 3

THE ROLE OF THE EXTRACELLULAR MATRIX CUES IN CELL
PROLIFERATION AND DRUG RESPONSE

3.1 Abstract
The tissue ECM has a crucial role in modulating the normal function of many
cell types in the tissue, and deregulation of this matrix can cause different types of
disease including cancers. The change from a normal ECM, which is the basement
membrane ECM, to the cancerous ECM, which is rich in fibrillar collagens, induced
some breast and liver cancer cells to be more resistant to sorafenib, and this trend is celltype dependent. The proliferation of many cancer cell lines was regulated by the substrate
modulus; however, the trend of proliferation with modulus also depends on the cell type.
High-throughput platforms were developed from different types of hydrogels such as
PAA, PEG, and PEG-PC. These platforms can be coupled with various types of ECM
protein or cocktail of ECM protein. These platforms can allow multiple drugs to be tested
with many cells on various moduli and proteins that capture the physicochemical
properties of the tissue ECM.
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3.2 Introduction
In drug development, multiple compounds are tested in plastic multi-well plates,
followed by preclinical and clinical trials. This process costs over one billion dollars, and
takes 11 to 15 years per drug on average [1]. The cost burden is partially caused by
inefficiencies in high-throughput screening, as small molecule candidates often show
efficacy in cells on plastic plates, but fail in animal or human trials. In order to improve
high-throughput screening, compounds should be tested in cells on biomaterial platforms
that have the ability to capture tissue properties. Traditionally, the cell-based highthroughput screening is usually done with cells plated on multi-well plastic plates such as
96- or 384- well plates. These plastic plates lack relevant chemical and physical cues,
which are found in the ECM of native tissues. The tissue ECM is much softer than plastic
plates, and it contains many growth factors and proteins that drive the cell biological
functions through binding to cellular growth factor receptors and integrins [2,3]. Often,
disruption in ECM homeostasis will lead to disorganized and deregulated ECM, resulting
in cancer development and growth [2,4,5]. Hence, it is necessary to develop a new drug
testing platform that not only includes human cell lines and appropriate growth factors
but also allows a precise control over integrin-binding and substrate stiffness. Many
groups are spurring the development of novel cell culture platforms for more rational and
predictive drug discovery [6–8]; however, I found that existing systems are either
cumbersome to use, or have limited adaptability. In response, I adapted the novel PEGPC hydrogel system, an easy to use biomaterial, which is optically transparent, forms gels
ranging from 1-10,000 kPa in Young's modulus, can be coupled with any protein or
peptide of interest, and rapidly polymerizes within 96-well plates [9]. This novel platform
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allowed me to quantify drug response in a high-throughput manner across a range of
stiffness and integrin-binding conditions.

3.3 Materials And Methods
3.3.1 Cell culture
All supplies were purchased from Life Technologies (Carlsbad, CA) unless
otherwise noted. Human breast cancer cell lines (MDA-MB-231, BT549, MCF7 and
SkBr3) were generous gifts from Dr. Shannon Hughes at the Massachusetts Institute of
Technology, and were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S)
at 37ºC and 5% CO2. Human hepatocellular carcinoma (HCC) cells (HEP3Bs, American
Type Culture Collection, Manassas, VA) were cultured in modified Eagle's medium
(MEM) supplemented with 10% FBS and 1% P/S at 37ºC and 5% CO2. Human breast
cancer cell lines HCC38 and AU565 were generous gifts from Dr. Mario Niepel at the
Harvard University, and they were cultured in Roswell Park Memorial Institute (RPMI)
medium supplemented with 10% FBS and 1% P/S at 37ºC and 5% CO2.
3.3.2 Protein coating and drug treatment on 96-well tissue culture plates
Sterile fibronectin protein solutions at different concentrations (0.5, 2.5, 5, 10
μg/cm2) were made by mixing human plasma fibronectin (EMD Millipore, Billerica,
MA) in a buffer solution (pH ~ 9.4 with acetic acid) that contains sodium carbonate
(Thermo Fisher Scientiﬁc, Waltham, MA) and sodium bicarbonate (Thermo Fisher
Scientiﬁc) at 15 mM and 35 mM, respectively. 100 μL of the fibronectin solution were
added to each well of 96-well plates, and the plates were incubated overnight at 4ºC.
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After incubation, the plates were washed 3 times with sterile phosphate buffered saline
(PBS) and then incubated with sterile 10 mg/mL of pluronic F127 (Sigma-Aldrich, St.
Louis, MO) dissolved in PBS. After a day of pluronic blocking at 4ºC, the plates were
washed 3 times with sterile PBS, and 10,000 cells/well were seeded in serum-free
medium. After 24 h, the medium was replaced with serum-free medium supplemented
with 20 ng/mL of platelet-derived growth factor (PDGF-BB, eBioscience, San Diego,
CA) and 20 ng/mL of epidermal growth factor (EGF, R&D Systems, Minneapolis, MN).
After 24 h, cells were treated with sorafenib (LC Laboratories, Woburn, MA) from 0 to
30 μM, diluted in growth factor supplemented serum-free medium. After 24 h, cell
proliferation was quantified with CellTiter 96 AQueous One Solution Cell Proliferation
Assay (Promega, Madison, WI) (20 μL of assay per well and 4 hour incubation) and read
at 490 nm (BioTek ELx800 microplate reader, BioTek, Winooski, VT). Cell apoptosis
was quantified with propidium iodine (Life Technologies). When the propidium iodide
was used, the medium in each well was aspirated and replaced with 200 μL of 4.5 μM
propidium iodide in PBS. After 30 minute incubation at 37ºC, the plate was read at
530/620 nm wavelength (emission/excitation) with a fluorescent plate reader
(Spectramax, Molecular Devices, Sunnyvale, CA). The inhibitory concentration at 50%
(IC-50) was calculated with Prism v5.04 (GraphPad Software, La Jolla, CA).
For the collagen-rich ECM coating, the protein cocktail (5 μg/cm2 total) was
comprised of 65% type I collagen (rat tail, Life Technologies), 33% type III collagen
(FibroGen, San Francisco, CA), and 2% fibronectin. The plates were incubated with both
collagen I and III mixed in 0.02 M acetic acid for a day and then with fibronectin in
sodium carbonate/bicarbonate buffer for another day before blocking with pluronic F127.

71

The plates were kept at 4ºC during the incubations and washed 3 times with PBS between
each incubation. For the basement membrane ECM, the protein cocktail (0.5 μg/cm2
total) was comprised of 46% collagen IV (Neuromics, Edina, MN), 46% fibronectin and
8% mouse laminin (Life Technologies). The procedure is similar to collagen-rich ECM
coating with the exception that the plate was incubated with collagen IV in 0.02 M acetic
acid for a day before incubating fibronectin and laminin mixed in sodium
carbonate/bicarbonate buffer for another day. After blocking with pluronnic F127, the
cell seeding and sorafenib treatment were similar to that described above.
3.3.3 Quantification of cell adhesion
HEP3B cells were seeded on a collagen-rich and basement membrane ECMcoated 96-well plate. After 24 h of adhesion, cells were washed with warm PBS, and 50
μL of 0.5 % (wt./v.) crystal violet (Thermo Fisher Scientiﬁc) in 20% (v./v.) methanol in
water were added to each well. The plate was incubated for 10 min at room temperature.
Then the plate was washed twice with PBS, and 100 uL of 1% (wt./v.) sodium dodecyl
sulfate (SDS) in water was added to solubilize the stain. The plate was shaken on a plate
shaker until all stains were dissolved, and then the absorbance was read at 570 nm on a
plate reader (BioTek).
3.3.4 Real-time quantification of Caspase 7 activity
The plasmids that were used for expression of caspase-activable green fluorescent
protein (CA-GFP) were a generous gift from Dr. Jeanne Hardy (Department of
Chemistry, University of Massachusetts Amherst). The plasmids were inserted into E.
Coli bacteria in a cuvette through electroporation with the Gene Pulser Xcell™ system
(Bio-Rad Laboratories, Hercules, CA). After electroporation, 100 μL of Super Optimal
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Broth (SOC) was added immediately into the cuvette, and the cuvette was incubated at
37ºC for 1 h. After incubation, 1 μL of bacterial solution was mixed with 99 μL of SOC
medium, and the mixture was spread evenly on an agar plate. The agar plate was made
with 1.5% wt./v. agar in Lysogeny Broth (LB) supplemented with 0.1 mg/mL ampicillin
(Thermo Fisher Scientiﬁc) (prepared at 500x or 50 mg/mL in water). The plate was
incubated at 37ºC for 16-20 h. After incubation, a colony was picked and incubated with
3 mL of LB medium, which is supplemented with 0.1 mg/mL ampicillin, for 16-20 h at
37ºC with shaking at 225 rpm. The plasmids were then purified using Pureyield™
Plasmid Miniprep System (Promega) following the manufacturer's protocol. The plasmid
concentrations were determined with the NanoDrop (Thermo Fisher Scientiﬁc).
HEP3B cells were allowed to adhere to a 24 well plate. The cells were transfected
with 1,000 ng of plasmid per well using Lipofectamine reagent (Life Technologies)
following the manufacturer's protocol. Briefly, the plasmids were diluted in 100 μL OptiMem (Life Technologies). 0.5 μL of PLUS reagent was added into the mixture, and it
was incubated for 15 min at room temperature. During the incubation, the cells were
washed with Opti-MEM, and the medium was replaced with Opti-MEM. After a 15 min
incubation, 2 μL of Lipofectamine reagent was added to the plasmid complex mixture,
and the mixture was incubated for 25 min before being transferred to the well. After 5 h,
the cells were washed and replaced with medium containing 10% FBS only. After 24 h,
the cells were detached and seeded onto a glass-bottom 24-well plate (Mat Tek, Ashland,
MA) coated with either collagen-rich or basement membrane ECM. After 24 h, the cells
were treated with 4 μM sorafenib, and live-cell imaging was performed with a Zeiss Axio
Observer Z1 microscope with a 63x oil immersion objective (Carl Zeiss AG,
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Oberkochen, Germany). Images were analyzed in ImageJ (NIH, Bethesda, MD). The
corrected total cell fluorescence (CTCF) was calculated from the following equation:
CTCF = Integrated Density - (area of selected cell x mean fluorescence of
background readings)
3.3.5 96-well hydrogel platform
Glass-bottom 96-well plates (no. 1.5 coverslip glass; In Vitro Scientific,
Sunnyvale, CA) were plasma treated (Harrick Plasma, Ithaca, NY) and subsequently
methacrylate-silanized with 2 vol% 3-(trimethoxysilyl) propyl methacrylate (SigmaAldrich, St. Louis, MO) in 95% ethanol (adjusted to pH 5.0 with glacial acetic acid) for 5
min, washed 3 times with 100% ethanol, and dried at 40 °C for 30 min.
To make PEG-PC hydrogels, PEGDMA (Mn 750, Sigma-Aldrich), from 0.6-9.1
wt%, was combined with 17 wt% 2-methacryloyloxyethyl phosphorylcholine (PC)
(Sigma-Aldrich) in phosphate buffered saline (PBS). These PEGDMA crosslinker
concentrations tune the Young's moduli of the resulting gels from 6 to 400 kPa [9].
Solutions were sterilized using a 0.2 μm syringe ﬁlter (Thermo Fisher Scientiﬁc) and
degassed by nitrogen sparging for 30s. Free-radical polymerization was induced by
addition of 0.05 wt% ammonium persulfate (APS) and 0.125 vol%
tetramethylethylenediamine (TEMED, Bio-Rad Laboratories). Hydrogels of 40 μL per
well in the 96-well plates were polymerized under nitrogen for 10 min.
To make polyacryamide (PAA) hydrogels, acrylamide (40 wt % acrylamide
solution) (A) and N, N'-methylenediacrylamide (2% bis solution) (B) are mixed together
at different wt. % in 1X phosphate buffered saline (PBS, pH 7.0) in order to create
hydrogels with various stiffnesses. Specifically, the combinations of 5%A/0.1%B,
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8%A/0.2%B, 8%A/0.4%B, 8%A/0.6%B, 15%A/1.2%B (v./v.) create hydrogels that have
these stiffnesses: 1, 22, 46, 52, and 308 kPa, respectively [10]. Solutions were sterilefiltered and degassed by nitrogen sparging. To induce polymerization in the 96-well
plates, APS and TEMED were used at 0.02 wt% and 0.05 vol%, respectively.
To make PEG hydrogels, PEGDMA was mixed with PBS at different
concentrations: 10, 15, 20, 25, 30 vol%. Solutions were sterile-filtered and degassed by
nitrogen sparging. APS and TEMED were used at 0.1 wt% and 0.25 vol%, respectively.
Post-polymerization, hydrogels were allowed to swell for 24 h in PBS, then
treated with 100 μL of sulfo-SANPAH (ProteoChem, Denver, CO; 0.6 mg/mL in pH 8.5
HEPES buffer) under UV light for 20 min, rinsed twice with HEPES buffer, and followed
immediately by incubation with protein mixtures overnight. ECM protein mixtures
defined as “bone” composed of 65% rat tail collagen I and 1% osteopontin (R&D
Systems) at 5 μg/cm2, "brain" composed of 50% fibronectin, 25% vitronectin (R&D
Systems), 20% tenascin C (R&D Systems), and 5% mouse laminin at 1 μg/cm2, or "lung"
composed of 33% mouse laminin, 33% collagen IV, 15% collagen I, 15% fibronectin,
4% tenascin C at 2 μg/cm2. When only collagen I was used, the concentration was 10
μg/cm2. All proteins were mixed in pH 3.8 PBS. Post-protein coupling, the gels were
rinsed twice with PBS, UV-sterilized for 1 h, and rinsed with sterile medium before cell
seeding.
3.3.6 Proliferation of breast cancer cells
For the proliferation experiments on PEG-PC coupled with collagen I, SkBr3 and
MDA-MB-231cells were seeded at 6,000 cells/well in serum-free DMEM with 1% P/S.
HEP3B cells were seeded at 6,000 cells/well in MEM media with 10% FBS and 1% P/S.

75

After 24 h, the media was changed to 10% FBS media. Media was replenished every 2
days. Five days after seeding, the proliferation was measured with the CellTiter96 assay
as described above.
For the proliferation experiments on PAA and PEG gels coupled with collagen I,
231s were seeded at 10,000 cells/well in DMEM with 10% FBS and 1% P/S. The
proliferation was measured 2 days after seeding.
For the proliferation experiments on PEG-PC gels coupled with either "bone",
"brain", or "lung" proteins, 231s and MCF7s were seeded at 6,000 cells/well in DMEM
with 10% FBS and 1% P/S; HCC38 and AU565 were seeded at 6,000 cells/well in RPMI
with 10% FBS and 1% P/S. The proliferation was measured 7 days after seeding.
3.3.7 Statistical Analysis
Statistical analysis was performed using Prism v5.04 (GraphPad Software, La
Jolla, CA). Statistical significance was evaluated by either using unpaired Student’s t
tests (with Welch’s correction as necessary) or one-way analysis of variance (ANOVA)
with a Tukey post-test. Data are reported as mean ± standard deviation. p ≤ 0.05 is
denoted with *, ≤ 0.01 with **, and ≤ 0.001 with ***; P > 0.05 is considered not
significant (“ns”).

3.4 Results
3.4.1 The response of cancer cells to sorafenib depends on both ECM proteins and
cell types
HEP3Bs were allowed to adhere to fibronectin coated on plastic plates at different
protein concentrations and treated with sorafenib for 24 h. Both the IC-50s obtained from
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the proliferation (Figure 3.1A) and apoptosis (Figure 3.1B) assays for sorafenib
treatments indicate no significant difference across various protein concentrations. This
result may suggest that the binding of HEP3Bs to fibronectin can be saturated at low
protein concentration, and thus increasing the ligand density will not significantly alter
HEP3Bs' responses to sorafenib. I also quantified the response of HEP3Bs to sorafenib in
the presence of different protein cocktails that combined various proteins instead of just
fibronectin. Similar to the results with fibronectin, the HEP3Bs' IC-50s were independent
of protein concentration for both basement membrane ECM (collagen IV, laminin, and
fibronectin) (Figure 3.2A) and collagen-rich ECM (collagen I, III, and fibronectin)
(Figure 3.2B). Interestingly, the IC-50s on the collagen-rich ECM were higher than those
on basement membrane ECM (4.6 vs. 3.1 μM). These results showed that the response of
HEP3B to sorafenib is more dependent on the types of ligand binding than the ligand
density.
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Figure 3.1 Sorafenib IC-50s of HEP3B cells across different fibronectin
concentrations. The inhibitory concentrations at 50% (IC-50s) of HEP3Bs are not
significantly different across different fibronectin concentrations. (A) IC-50s were
calculated from the proliferation measurements with the CellTiter96 assay. (B) IC-50s
were calculated from the apoptosis measurement with the propidium iodide assay.
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Figure 3.2 Sorafenib IC-50s of HEP3B cells across different protein mixture
concentrations. The IC-50s of HEP3Bs are more dependent on protein types than protein
concentrations. The IC-50s on (A) the basement membrane ECM (collagen IV, laminin,
and fibronectin) are lower than those on (B) the collagen-rich (collagen I, III, and
fibronectin), and the IC-50s on each ECM are similar across different concentrations.
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Motivated by the interesting observations above, I quantified the IC-50s of the
other cell lines in response to sorafenib when placed on 5 μg/cm2 of collagen-rich ECM
or 0.5 μg/cm2 of basement membrane ECM (Figure 3.3). The IC-50s of HEP3Bs, MDAMB-231s, and BT549s on collagen-rich ECM were 26%, 48%, and 54% higher than
those on basement membrane ECM, respectively. However, the IC-50s of MCF7 and
SkBr3 were not significantly different between the two ECMs. Therefore, the ability of
cells to sense the differences in ECM binding was also cell type dependent. As a proof of
concept, I used the crystal violet assay, which contains a DNA binding molecule, to
quantify the HEP3B cell adhesion between the two ECMs. There was not any significant
difference in the number of adherent cells between the collagen-rich and basement
membrane ECMs (Figure 3.4). Thus, the difference in HEP3Bs' IC-50s between the two
ECMs could not be caused by differences in cell adhesion.
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Figure 3.3 Sorafenib IC-50s multiple cell types across different protein mixture
concentrations. Most of cell lines are more resistant to sorafenib when adhering
collagen-rich ECM. HEP3B, MDA-MB-231, and BT549 are sensitive to the change in
ECM, whereas SkBr3 and MCF7 are not.
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Figure 3.4 Adhesion quantification of HEP3B cells. The same amount of HEP3B cells
adhere to both ECMs. Adhesion of HEP3Bs, which were quantified by crystal violet 24 h
after cell seeding, is not significantly different between collagen-rich and basement
membrane ECMs.
In addition, I quantified the response of HEP3B cells to sorafenib through the
measurement of caspase-7 activity in real time. Caspase signaling plays an important role
in regulating cellular apoptosis. Caspase-3/ -6/-7 are known to be the apoptosis
executioners, which can cause cell shrinkage, membrane blebbing, and DNA
fragmentation. These caspases can be activated by other upstream caspases such as
caspase-2/-8/-9/-10 [11]. I transfected HEP3Bs with DNA plasmids that induced the
expression of a green fluorescent protein (GFP). The GFP activity is fully quenched by a
short peptide that contains the caspase-7 recognition site DEVA [12]. When caspase-7 is
activated, it will cleave the quenching peptide to release the GFP. Therefore, the amount
of GFP detected is correlated to the amount of caspase activation. Images of the GFP
activation were taken in real time after HEP3Bs were treated with 4 μM of sorafenib
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(Figure 3.5). However, the CTCF, which was quantified by imageJ, did not show any
difference between the two ECMs (Figure 3.6).
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Figure 3.5 Expression of caspase-activable green fluorescent protein (CA-GFP) in
HEP3B cells. HEP3Bs were transfected with plasmids that induced the expression of
CA-GFP and allowed to adhere to the basement membrane ECM before treating with
sorafenib. The GFP intensity keeps increasing over 24 hour under 4μM sorafenib
treatment. Scale bar is 20 μm.
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Figure 3.6 Fluorescent intensity of CA-GFP in HEP3B cells. The corrected total cell
fluorescence increases over time and is similar between the two ECMs.
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3.4.2 Substrate modulus affects cell proliferation
I adapted the PEG-PC, PAA, and PEG hydrogels into high-throughput platforms,
which could be quickly used to study the relationship between mechanobiology and drug
response. A representative image of PEG-PC gels in a 96-well plate is shown in Figure
3.7. The relationship between substrate modulus and cell proliferation was investigated
with HEP3Bs, MDA-MB-231s, and SkBr3s. All cell lines were seeded on PEG-PC gels
coupled with 10 μg/cm2 collagen I. Both MDA-MB-231 and HEP3B cells showed an
increase in proliferation with increasing PEG-PC modulus (Figure 3.8A and B). HEP3Bs
were the most stiffness-sensitive cell line. Its proliferation increased nearly 3 fold
between 18 and 165 kPa gels, whereas 231s showed a 26% increase in proliferation
between 18 and 26 kPa gels before leveling off at higher stiffnesses. SkBr3 proliferation
decreased approximately 50% between the softest and stiffest gel conditions (Figure
3.8C). MDA-MB-231s showed similar trends in increasing proliferation with increasing
substrate modulus when placed on PAA gels (Figure 3.9) and PEG gels (Figure 3.10).
While the proliferation on PAA gels showed a steady increase across the range of
stiffness from 1 to 308 kPa, the proliferation trend on PEG-only gel was much more
similar to PEG-PC gels with increasing proliferation at the lower stiffness range and
saturating at higher stiffnesses (the modulus of 18.4% PEG-only gel was measured to be
174 ± 9.8 kPa).
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Figure 3.7 PEG-PC high-throughput platform. The high-throughput platform consists
of a black-walled, glass bottom plate, with PEG-PC gels cast in each of the inner 6x10
wells.
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A

B

C

Figure 3.8 The proliferationof 231, HEP3B, and SkBr3 cells. The proliferation of (A)
231, (B) HEP3B, and (C) SkBr3 cells on PEG-PC, which is coupled with collagen I,
from 18 to 400 kPa was quantified 5 days post-seeding. Results are the fold changes
relative to the softest condition (18 kPa). HEP3Bs' proliferation is strongly dependent on
substrate modulus whereas the proliferations of 231s and SkBr3s are less sensitive to
substrate modulus and display opposing trends. Figure adapted with permission from [9].
© 2013 American Chemical Society.
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Figure 3.9 The proliferation of 231 cells on PAA gels. The proliferation of 231 cells on
PAA gels coupled with collagen I increases with increasing substrate modulus. The
proliferation was quantified 2 day post-seeding.
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Figure 3.10 The proliferation of 231 cells on PEG-only gels. The proliferation of 231
cells on PEG-only gels coupled with collagen I increases with increasing PEGDMA
concentrations at lower concentrations. The proliferation was quantified 2 day postseeding.
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3.4.3 Proliferation can be regulated by both substrate modulus and ECM proteins
MDA-MB-231s, MCF7s, HCC38s, and AU565s were placed on 6, 23, and 400
kPa PEG-PC gels that were coupled ECM proteins found in the brain (fibronectin,
vitronectin, tenascin C, laminin), lung (laminin, collagen IV, collagen I, fibronectin,
tenascin), and bone (collagen I and osteopontin). Both 231s and HCC38s proliferated
more on lung and bone compared to brain, but there was not any significant difference
between lung and bone (Figure 3.11A and B). However, AU565s were most proliferative
on lung (Figure 3.11C), whereas MCF7s showed similar proliferation across the three
different environments (Figure 3.11D).
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Figure 3.11 The proliferation of many cell types across different
microenvironments. The proliferation on different microenvironments is cell-type
dependent. Both (A) 231s and (B) HCC38s show similar trends in proliferation and are
more proliferative on lung and bone compare to brain microenvironment. (C) AU565s'
proliferation is strongly dependent on types of microenvironments, whereas (D) MCF7s
are not sensitive to the changes in microenvironments.
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3.5 Discussion
The tumor microenvironment plays an important role in mediating signals for
cancer cells to grow, resist chemotherapies, and metastasize to distal tissues [13–16].
Cancer cells can receive biochemical signals from the tumor microenvironment through
growth factors released in the tumor tissue or binding of their integrins to ECM proteins.
Integrins are heterodimers composed of an α- and a β-subunits. Different
heterodimerizations of α- and β-subunits are required when the cells bind to different
types of ECM protein [17]. Binding of integrins to ECM proteins can mediate many
different downstream signaling pathways such as PI3K/Akt and Ras/Raf/ERK to promote
cell survival and proliferation or Rho/ROCK pathway to enhance cell motility [18], and
integrin binding can also induce the drug resistance of cancer cells to other
chemotherapeutic drugs [19]. Therefore, the switching of the basement membrane ECM,
which is a representative of normal ECM [4], to the collagen-rich ECM, which is a
representative of tumor ECM [4], can mediate resistance to sorafenib, which targets the
Raf/ERK pathway [20]. The sorafenib resistance was observed in several cell lines such
as HEP3Bs, 231s, and BT549s (Figure 3.3). Binding to collagen I was shown to mediate
ERK signaling in T-Lymphocytes, whereas binding to laminin or fibronectin did not
sustain ERK activation [21]. Thus, the presence of relevance ECM binding proteins is
necessary for cell-based drug screening. Integrin structure, expression and downstream
signaling was found to be heterogeneous across breast cancer cell lines [22]. Perhaps, this
could be an explanation for the heterogeneous responses among different cell types
toward the changes in ECM proteins (HEP3B, MDA-MB-231, and BT549 vs. MCF7 and
SkBr3) and the insensitivity of HEP3Bs toward the changes in protein concentration.
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Although HEP3B cells seeded on collagen-rich were more resistant to sorafenib, the
caspase-7 activation was similar between the two ECMs (Figure 3.6). The GFP was only
activated after the cells were already dead and round, from 8 h to 24 h (Figure 3.5). There
was not any change in GFP detected between 0.5 h and 8 h during the transition from
being alive to being dead. These results can be indicative of non-caspase induced death
mechanism in HEP3B liver cancer cells. In two other liver cancer cell lines, sorafenib
was shown to induce cell death via caspase-3 activation in HEPG2, but not in PCL/PRF/5
cells [20]. Sorafenib was also shown to induce apoptosis via nuclear translocation of
apoptosis-inducing factor (AIF) in melanoma cells [23]. A few cells were found to have
caspase-7 activated when sorafenib was added for just 0.5 h (cells in the bottom left
corner of 0.5 h image, Figure 3.5). These cells could be dying via caspase-7 induced
pathway due to natural causes before the addition of sorafenib since 0.5 h is too short for
sorafenib to have any major effect.
As a proof of concept, cell proliferation was shown to be regulated by substrate
modulus when cells were placed on PEG, PEG-PC, and PAA hydrogels coupled with
collagen I (Figure 3.8, 3.9, 3.10). However, this modulus-regulated cell proliferation is
cell-type dependent. Thus it is important to include relevant tissue modulus into the drug
screening process since many drugs work by a mechanism of dampening cell
proliferation.
When both substrate modulus and ECM proteins were varied, the substrate
modulus and the ECM proteins synergistically regulate cell proliferation in certain cell
type. MCF7 cell proliferation was insensitive to changes in microenvironments, and
AU565 cells proliferated the most on the intermediate gel coupled with lung proteins
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(Figure 3.11C). Thus, proliferation in this cell line is not a function of substrate modulus.
Both MDA-MB-231 and HCC38 showed the similar proliferation trend as they
proliferated the most on lung and bone gels. This could be due to the fact that lung and
bone gels are stiffer than brain gels. 231s' proliferation saturated at gels that were stiffer
than 26 kPa when they were seeded on collagen I (Figure 3.8A), and this trend is similar
to the proliferation trend on brain (6 kPa), lung (23 kPa), and bone (400 kPa). This could
infer that 231 proliferation is more strongly influenced by stiffness than the change in
ECM proteins. Interesting, both 231s and HCC38s are triple negative, whereas AU565
and MCF7 are HER2+ and luminal, respectively. Therefore, the relationship between cell
proliferation and microenvironments could be subtype-dependent.

3.6 Conclusions
I have shown that both ECM proteins and substrate modulus play an important
role in regulating cell proliferation and response to drugs. The interactions between cells
and these physicochemical cues are also dependent on cell types and subtype. Thus, both
of these variables should be included in the cell-based high-throughput drug screening in
order to bridge the gap between in vitro and in vivo models. The synthetic biomaterial
platforms PEG-PC, PAA, and PEGDMA, which allow independent control of mechanical
properties and ligand binding, were developed and proven to be useful for quantifying
cell-matrix interactions in a high-throughput manner.
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CHAPTER 4

SORAFENIB RESISTANCE AND JNK SIGNALING IN CARCINOMA
DURING EXTRACELLULAR MATRIX STIFFENING

4.1 Abstract
Tumor progression is coincident with mechanochemical changes in the
extracellular matrix (ECM). I hypothesized that tumor stroma stiffening, alongside a shift
in the ECM composition from a basement membrane-like microenvironment toward a
dense network of collagen-rich fibers during tumorigenesis, confers resistance to
otherwise powerful chemotherapeutics. To test this hypothesis, I applied the highthroughput drug screening PEG-PC platform that I created as described in Chapter 3, and
customized it to capture the stiffness and integrin-binding profile of in vivo tumors. I
report that the efficacy of a Raf kinase inhibitor, sorafenib, is reduced on stiff, collagenrich microenvironments, independent of ROCK activity. Instead, sustained activation of
JNK mediated this resistance, and combining a JNK inhibitor with sorafenib eliminated
stiffness-mediated resistance in triple negative breast cancer cells. Surprisingly, neither
ERK nor p38 appears to mediate sorafenib resistance, and instead, either ERK or p38
inhibition rescued sorafenib resistance during JNK inhibition, suggesting negative
crosstalk between these signaling pathways on stiff, collagen-rich environments. Overall,
I discovered that β1 integrin and its downstream effector JNK mediate sorafenib
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resistance during tumor stiffening. These results also highlight the need for more
advanced cell culture platforms, such as this high-throughput PEG-PC system, with
which to screen chemotherapeutics.

4.2 Introduction
The tumor microenvironment plays an important role in providing a niche to
nurture the growth of cancer cells [1]. Recently, stromal cells, growth factors, cytokines,
and ECM proteins in the tumor microenvironment have been implicated in promoting
resistance to chemotherapeutics as well [2, 3]. Specifically, certain stromal growth factors
mediate cell proliferation in the presence of otherwise powerful chemotherapeutic drugs.
For example, hepatocyte growth factor (HGF) imparts resistance to vemurafenib in
melanoma [4, 5], and TGF-β induces the expansion of cancer stem-like cells, which are
responsible for chemotherapy-resistance and relapses [6]. These growth factors are
generally thought to be released by local stromal fibroblasts, which upon DNA-damage
from treatments with a combination of mitoxantrone and docetaxel, or radiation stimulate
prostate cancer cell proliferation and invasion through β-catenin signaling [7]. In addition
to soluble growth factors, a change in adhesive ECM proteins in the tissue can confer
resistance to chemotherapeutics via integrin-mediated signaling [8-11].
This evolution in the microenvironment during tumor progression is mediated by
stromal fibroblasts, which differentiate into myofibroblasts [12] and cancer-associated
fibroblasts (CAFs) [13], and remodel the ECM by breaking down the basement
membrane and depositing fibril forming collagens [14-16]. The increase in crosslinked
fibrous collagens results in tissue stiffening [17, 18], which stimulates cell proliferation
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[17, 19], invasion and intravasation [20, 21], disrupts cell-cell adhesion [22], and alters
cell sensitivity to growth factors [23], while simultaneously limiting the diffusion of
therapeutic agents into the tumor [24].
I hypothesized that these mechanochemical changes in the ECM during tumor
progression may induce drug resistance in carcinoma. Testing this hypothesis required a
drug testing platform that included not only human cell lines and appropriate growth
factors, but also tailored control over integrin-binding and ECM stiffness. Therefore, I
applied the high-throughput PEG-PC platform, which was described in chapter 3, as a
tool for the study to validate this hypothesis.
The role of stiffness in regulating drug response was explored by Schrader et al.,
who observed a reduction in apoptosis of cells on stiff substrates when treated with
cisplatin [25]. Also, Zustiak et al. reported cell line-dependent stiffness sensitivity to
paclitaxel [26]. Sorafenib was developed as a Raf kinase inhibitor [27], and unlike these
previously tested drugs, there is no obvious link between this signaling pathway and
ECM stiffness. Phosphorylation of ERK, a downstream effector of Raf kinase, has been
implicated in controlling cell proliferation during ECM stiffening [19, 28], so I
hypothesized that sorafenib efficacy could be hampered in stiff environments,
contributing at least partially to sorafenib's modest clinical efficacy [29].
To capture the evolution of the tumor microenvironment during disease
progression, I formed hydrogel environments with a range of stiffnesses, including either
basement membrane-like ECM proteins [30], or a collagen-rich inflammatory ECM [21].
I examined whether stiff environments protected carcinoma cells from sorafenib
treatment, and if this drug resistance was mediated by the canonical Rho-ROCK and β1
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integrin signaling pathways. Motivated by a targeted phospho-proteomic screen, I also
quantified the role of ERK, Akt, JNK and p38 signaling during cell response to sorafenib
on stiff substrates. The results demonstrate the utility of the tunable, high-throughput
PEG-PC biomaterial platform in drug screening, and identify an exciting new mechanism
to increase the efficacy of sorafenib in stiff tumor environments.

4.3 Materials And Methods
4.3.1 Cell culture
All supplies were purchased from Life Technologies (Carlsbad, CA) unless
otherwise noted. Human breast cancer cell lines (MDA-MB-231, BT549, and SkBr3)
were generous gifts from Dr. Shannon Hughes at the Massachusetts Institute of
Technology, and were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S)
at 37ºC and 5% CO2. Human hepatocellular carcinoma (HCC) cells (HEP3Bs, American
Type Culture Collection, Manassas, VA) were cultured in modified Eagle's medium
(MEM) supplemented with 10% FBS and 1% P/S at 37ºC and 5% CO2. MDA-MB-231
expressing DsRed and DsRed-let7c-sensor were generous gifts from Dr. D. Joseph Jerry
at the Department of Veterinary and Animal Science, University of Massachusetts
Amherst. These two cell lines were cultured in DMEM:F12 supplemented with 14 mM
sodium bicarbonate, 10 mM HEPES, and 10% FBS, 10 μg/mL Insulin, 1x
antibiotic/antimycotic, 15 μg/mL gentamicin, and 2 mM L-Glutamine.
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4.3.2 96-well hydrogel platform
Glass-bottom 96-well plates (no. 1.5 coverslip glass; In Vitro Scientific,
Sunnyvale, CA) were plasma treated (Harrick Plasma, Ithaca, NY) and subsequently
methacrylate-silanized with 2 vol% 3-(trimethoxysilyl) propyl methacrylate (SigmaAldrich, St. Louis, MO) in 95% ethanol (adjusted to pH 5.0 with glacial acetic acid) for 5
min, washed 3 times with 100% ethanol, and dried at 40 °C for 30 min. PEGDMA (Mn
750, Sigma-Aldrich),

from 0.6-9.1

wt%,

was combined

with 17 wt% 2-

methacryloyloxyethyl phosphorylcholine (PC) (Sigma-Aldrich) in phosphate buffered
saline (PBS). These PEGDMA crosslinker concentrations tune the Young's moduli of the
resulting gels from 6 to 400 kPa [31]. Solutions were sterilized with a 0.2 μm syringe
ﬁlter (Thermo Fisher Scientiﬁc, Waltham, MA) and degassed by nitrogen sparging for
30s. Free-radical polymerization was induced by addition of 0.05 wt% ammonium
persulfate (APS) and 0.125 vol% tetramethylethylenediamine (TEMED, Bio-Rad
Laboratories, Hercules, CA). Hydrogels of 40 μL per well in the 96-well plates were
polymerized under nitrogen for 10 min.
Post-polymerization, hydrogels were allowed to swell for 24 hours in PBS, then
treated with 100 μL of sulfo-SANPAH (ProteoChem, Denver, CO; 0.6 mg/mL in pH 8.5
HEPES buffer) under UV light for 20 min, rinsed twice with HEPES buffer, and followed
immediately by incubation with protein mixtures overnight. ECM protein mixtures were
defined as either “basement membrane” composed of 46% human collagen IV
(Neuromics, Edina, MN), 46% human fibronectin (EMD Millipore, Billerica, MA), and
8% mouse laminin at 5 μg/cm2, buffered in pH 7.0 PBS, or “collagen rich” composed of
65% rat tail collagen I, 33% human collagen III (FibroGen, San Francisco, CA), and 2%
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fibronectin at 5 μg/cm2, buffered in pH 3.8 PBS. Post-protein coupling, the gels were
rinsed twice with PBS, UV-sterilized for 1 h, and rinsed with sterile medium before cell
seeding.
4.3.3 Quantification of drug resistance
Cells were seeded onto gel surfaces at a density of 31,000 cells/cm2 in serum-free
medium supplemented with 20 ng/mL of platelet-derived growth factor (PDGF-BB,
eBioscience, San Diego, CA) and 20 ng/mL of epidermal growth factor (EGF, R&D
Systems, Minneapolis, MN). After 24 h, cells were treated with sorafenib (LC
Laboratories, Woburn, MA) from 0 to 120 μM, diluted in growth factor-supplemented
serum-free medium. After 24 h, I measured cell proliferation with CellTiter 96 AQueous
One Solution Cell Proliferation Assay (Promega, Madison, WI) at 490 nm (BioTek
ELx800 microplate reader, BioTek, Winooski, VT). The concentration of sorafenib that
reduced cell proliferation by 50% (IC-50) was calculated with Prism v5.04 (GraphPad
Software, La Jolla, CA). In some experiments, sorafenib was also co-administered with:
an anti-β1 integrin antibody (clone P5D2, R&D Systems, 0.5 μg/mL), p160ROCK
inhibitor (Y-27632, R&D Systems, 10 μM), EGF receptor (EGFR) inhibitor (AG1478,
AG Scientific, San Diego, CA, 1 μM), JNK inhibitor (SP600125, LC Laboratories, 20
μM), p38 inhibitor (BIRB796, LC Laboratories, 1 μM), or ERK inhibitor (FR180204,
Sigma-Aldrich, 20 μM). Dimethyl sulfoxide (Sigma-Aldrich) was used as a vehicle
control in all experiments. I also verified that cell proliferation measurements
approximately linearly correlated to cell count (Figure 4.1).
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Figure 4.1 MTS assay linearly correlates with raw cell counts. 231 cells were seeded
at different cell densities on 400 kPa gels, and the MTS assay was run 24-hour postseeding. The resulting absorbance (proliferation, y-axis) linearly correlates with initial
cell number (x-axis) with a R2 of 0.9933. Figure adapted with permission from [74]. ©
2014 Elsevier, Inc.
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4.3.4 Immunofluorescent imaging
18 mm glass coverslips (Thermo Fisher Scientiﬁc, Waltham, MA) were plasma
treated, methacrylate-silanized, and dried at 120 °C for 15 min. 80 μL PEG-PC hydrogels
were polymerized with APS and TEMED between a methacrylated-silanized coverslip
and an untreated coverslip for 20 min on the bench. After polymerization, the hydrogels
were allowed to swell in PBS, and the non-treated coverslips were removed easily with
fine forceps. Swollen gels on coverslips were transferred to 12-well tissue culture dishes,
coupled with protein mixtures as described above, rinsed 3 times with PBS, and UVsterilized for 1 h prior to cell seeding.
Cells were seeded at a density of 10,000 cells/cm2 in growth factor-supplemented
serum-free medium and allowed to adhere for 24 hours. Cells were rinsed three times
with warm PBS, fixed with 4% formaldehyde, permeabilized with Tris-buffered saline
(TBS) containing 0.5% Triton X-100 (Promega), and blocked with AbDil (2 wt.% BSA
in TBS with 0.1% Triton X-100, TBS-T). F-actin was labeled with Alexa Fluor 555conjugated phalloidin for 1 h. Vinculin was labeled with a monoclonal mouse antivinculin antibody (Sigma-Aldrich) for 1 h, followed by an anti-mouse FITC secondary
antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 h. Cell nuclei
were labeled with DAPI (MP Biomedicals, Santa Ana, CA) for 5 min. Each sample was
treated with ProLong Gold antifade reagent for 5 min before imaging on a Zeiss Axio
Observer Z1 microscope with a 63x oil immersion objective (Carl Zeiss AG,
Oberkochen, Germany), and images were compiled in ImageJ (NIH, Bethesda, MD).
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4.3.5 Multiplex phospho-protein quantification
MDA-MB-231 cells ('231s') were seeded at 50,000 cells/cm2 on 6 and 400 kPa 18
mm diameter coverslip-mounted gels in 12-well plates. Immediately after seeding, at 0
min, 30 min, 1 h, 2 h, 4 h, 6 h, and 24 h time points, coverslips were transferred to a new
12-well plate on ice, the gels were washed once with ice-cold Bioplex cell wash buffer
(Bio-Rad, Hercules, CA), and lysed with ice-cold lysis buffer (Bioplex cell lysis buffer,
Bio-Rad) containing protease (EDTA-free Protease Inhibitor Cocktail Tablets, Roche,
Indianapolis, IN) and phosphatase (2x phosphatase inhibitors cocktail-II, Boston
Bioproducts, Boston, MA) inhibitors. Separately, cells were allowed to adhere for 24
hours, treated with sorafenib, and lysates were collected at 0 min, 1 h, 5 h, 15 h, and 24 h
time points after sorafenib treatment. Total protein concentration was quantified with a
BCA protein assay (Thermo Scientific, Rockford, IL). Lysate concentrations were
adjusted to 100 μg/mL, and the phosphorylation levels of ERK1/2, Akt, JNK, and p38
were quantified with a MAGPIX (Luminex, Austin, TX) with Bio-Plex Pro™ phosphoERK1/2, phospho-Akt, phospho-JNK, and phopho-p38 magnetic beads (Bio-Rad),
according to the manufacturer instructions.
4.3.6 Quantification of mammary stem/progenitor cells
MDA-MB-231s expressing DsRed-let7c-sensor were seeded at 3,100 cells/cm2 on
18-mm gel-laden coverslips, which were coupled with collagen-rich ECM, in the same
cell-culture medium. The medium was replenished every other day, and the gels were
imaged at day 1, 3, 5, and 7. Then the number of red cells was manually counted from the
images.

106

When flow cytometry was used to quantify the number of progenitor cells, cells
were collected from the gels on day 7 and resuspended in 1x PBS supplemented with 0.5
wt. % of BSA and 1 mM Ethylenediaminetetraacetic acid (EDTA). The cell suspension
was filtered with a cell strainer (Thermo Fisher Scientiﬁc) to eliminate large cell clumps.
The Fluorescence-Activated Cell Sorting (FACS) data were collected with a total of
100,000 events using LSRII (BD Biosciences, San Jose, CA) and analyzed with BD
FACSDiva Software (BD Biosciences).
4.3.7 Statistical analysis
A one-way analysis of variance (ANOVA) with a Tukey post-test was performed
with Prism v5.04 (GraphPad Software). Data are reported as mean ± standard error. p ≤
0.05 is denoted with *, ≤ 0.01 with **, and ≤ 0.001 with ***; P > 0.05 is considered not
significant (“ns”).

4.4 Results
4.4.1 Carcinoma cell response to sorafenib on PEG-PC hydrogels
I created a high-throughput biomaterial platform to rapidly assay cell responses to
chemotherapeutic drugs in different mechanochemical environments (Figure 4.2). In
particular, I focused on how these changes perturbed the efficacy of sorafenib, a Raf
kinase inhibitor approved for thyroid, kidney and liver cancer, but which has had limited
clinical success [29, 32, 33]. One potential cause of drug resistance by carcinoma cells
might be the stiffening of the tumor environment itself, and so I quantified the responses
of a liver cancer cell line and three breast cancer cell lines to sorafenib on PEG-PC of
increasing stiffness (Figure 4.3).
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Figure 4.2 High-throughput biomaterial platform for drug screening. (A) The high-throughput
platform consists of a black-walled, glass bottom plate, with PEG-PC gels cast in each of the inner 6x10
wells. (B) Gels can be functionalized with any protein or peptide of interest, and they support the
adhesion and growth of carcinoma cells. I used this platform to test carcinoma cell response to a kinase
inhibitor (sorafenib) as a function of underlying gel stiffness and ECM adhesive protein cocktail. (C) A
representative graph of SkBr3 proliferation (y-axis) in response to sorafenib (x-axis) across a range of gel
stiffness (colors) demonstrates the IC-50 calculation. Figure adapted with permission from [74]. © 2014
Elsevier, Inc.

Figure 4.3 Representative images of cells adhering on 165 kPa gels coupled with
collagen-rich ECM in 96-well plate. (A) MDA-MB-231 (B) BT549 (C)SkBr3 (D)
HEP3B. Scale bar is 100 μm.
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In all cell lines, I consistently observed a significant increase in sorafenib IC-50,
the concentration at which the proliferation was dampened by half, with increasing
substrate stiffness (Figures 4.4A-B). I observed this phenomenon on both the basement
membrane-like ECM (Figure 4.4A), and the collagen-rich ECM (Figure 4.4B),
demonstrating that this stiffness-induced drug resistance is maintained even with
alterations in integrin binding. Two of the breast cancer cell lines I tested, the SkBr3s and
231s, were the most drug resistant cell lines on the basement membrane ECM (Figure
4.4A). When I normalized the IC-50s within each cell line to the softest condition, I
observed that these two cell lines also showed the most stiffness-induced resistance to
sorafenib, with 3.7 and 3 fold increases in IC-50 on the stiffest gels when compared to the
softest condition, respectively (Figure 4.5A). On the collagen-rich mixture, again the 231
and SkBr3s were the most drug resistant cell lines (Figure 4.4B), but, interestingly, the
HEP3B cell line was the most stiffness sensitive (Figure 4.5B). Altogether, on the
collagen-rich ECM, the SkBr3 and 231 cell lines are more sorafenib resistant across all
gel conditions. Stiffness increases their sorafenib resistance, but they appear less stiffness
sensitive than the HEP3Bs because the HEP3Bs are, overall, less resistant to sorafenib.

110

B

A

60

60

*
***

30

IC-50 (µM)

40

**

20

HEP3B
BT-549
MDA-MB-231
SkBr3

50

HEP3B
BT-549
MDA-MB-231
SkBr3

50

IC-50 (µM)

Collagen-rich ECM

Basement membrane ECM

40
*
*

30

20

**

10

10

0

0
0

100

200

300

200

100

0

400

Young's Modulus (kPa)

300

400

Young's Modulus (kPa)

C

D
1.2

1.2

2 h (collagen-rich ECM)
HEP3B
BT-549
MDA MB 231
SkBr3

1.0

0.8

0.6

***
***

***
***

0.4
*

*

Proliferation (abs. unit)

Proliferation (abs. unit)

**

0.2

24 h (collagen-rich ECM)

1.0

**

0.8

0.6

0.4

0.2

0.0
0

100

0.0

400

300

200

0

200

100

300

400

Young's Modulus (kPa)

Young's Modulus (kPa)

E
100

231s, collagen-rich ECM

IC-50 (µM)

80

Day 1
Day 5
*

60

40
*

20

0
0

100

200

300

400

Young's Modulus (kPa)

Figure 4.4 Cells on stiff substrates resist sorafenib. The IC-50 (from proliferation
measurements) of HEP3B (orange), BT-549 (blue), MDA-MB-231 (red), and SkBr3
(green) cells increases with stiffness on both (A) basement membrane ECM proteins and
(B) collagen-rich ECM proteins. On the collagen-rich ECM, the same proliferation assay
without sorafenib at (C) 2 hours and (D) 24 hours post-seeding demonstrates that
differences in initial cell adhesion or proliferation do not explain the results in A and B
for each cell line. (E) Resistance to sorafenib of 231 cells is heightened and maintained at
longer (5 days, red) culture times on the gels. Statistics shown are with respect to the
softest gel condition, with the exception of the BT549 cells in D which were significantly
different when comparing 50 and 400 kPa gels. N ≥ 3 independent biological replicates,
and N = 3 technical replicates. Figure adapted with permission from [74]. © 2014
Elsevier, Inc.
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Figure 4.5 Normalized cell proliferation in response to stiffness. (A) and (B) are the
data from Figure 2, re-drawn with each cell line internally normalized to the softest gel
condition. (A) On the basement membrane proteins, SkBr3 cells were the most stiffness
sensitive cell line, whereas (B) HEP3B cells were the most stiffness sensitive cell line on
collagen-rich proteins. Statistics are relative to the soft gel conditions. Figure adapted
with permission from [74]. © 2014 Elsevier, Inc.
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Neither initial cell adhesion to the gels, nor proliferation at 24 hours showed the
same consistent trends as drug resistance, ruling them out as significant contributors to
sorafenib resistance (Figures 4.4C-D and Figure 4.6). I also cultured the 231 cells for five
days prior to sorafenib treatment and found that the cells responded to sorafenib in the
same manner as compared to dosing 24 hours post-seeding, but with larger IC-50s due to
cell proliferation in the days prior to drug treatment (Figure 4.4E). This result
demonstrates that the observed stiffness-mediated drug resistance is maintained at longer
time points of culture.
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Figure 4.6 Spearman correlation between proliferation and IC-50s. Early cell
adhesion does not correlate with stiffness-mediated sorafenib resistance. (A) HEP3B, (B)
MDA-MB-231, (C) BT549, (D) SkBr3. With the exception of the HEP3B cell line (A, 24
hours only), no cell lines showed a positive Spearman correlation between the MTS
reading (y-axis) at 2 (circles) or 24-hours (squares) post seeding and the observed IC-50
value of sorafenib treatment (x-axis). Different colors represent the values at the different
stiffness gels. Figure adapted with permission from [74]. © 2014 Elsevier, Inc.
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4.4.2 Cytoskeletal tension and sorafenib resistance
Given the known role of substrate stiffness in influencing cell proliferation via the
canonical Rho-ROCK pathway [19, 28], I hypothesized that intracellular tension was the
most probable mechanism by which increasing stiffness protected cells from sorafenib. I
quantified cell area and imaged F-actin organization in response to increasing substrate
stiffness for the two most drug resistant cell lines (231 and SkBr3, Figure 4.7A-D).
Interestingly, on the collagen-rich ECM, cell spread area had a biphasic dependence on
substrate stiffness, whereas cell spread area increased with stiffness on the basement
membrane proteins. This result does not match the observed drug resistance results
(compare Figures 4.7B and D with Figures 4.4A-B), and implies that intracellular tension
does not exclusively explain the observed stiffness-mediated resistance on collagen-rich
ECM.

Figures 4.7A-D also demonstrate that integrin binding (via ECM proteins)

influences the sensitivity of cell area to substrate stiffness.
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Figure 4.7 Sorafenib resistance is not mediated by cytoskeletal tension. Both MDAMB-231s (A-B) and SkBr3s (C-D) show a biphasic relationship between cell spread area
and stiffness on the collagen-rich ECM, and increasing spread areas on the basement
membrane ECM. In A and C, cells were fixed and stained for F-actin (red), vinculin
(green), and the nucleus (DAPI, blue). (E) MDA-MB-231 stiffness-induced drug
resistance is significantly reduced when sorafenib is co-administered with an antibody to
β1 integrin (compare black and blue lines), whereas inhibitors to ROCK (red) and EGFR
(green) do not affect the stiffness-induced sorafenib resistance. (F) Neither the ROCK
nor EGFR inhibitors, nor the β1 integrin antibody effectively altered the response to
sorafenib in the SkBr3s. Statistics are with respect to the softest gel condition. N ≥ 3
independent biological replicates, and N = 3 technical replicates. Scale bar is 20 µm.
Figure adapted with permission from [74]. © 2014 Elsevier, Inc.
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I further examined the potential role of intracellular tension in mediating stiffnessinduced sorafenib resistance via ROCK activity. ROCK is a downstream effector of
RhoA, a GTPase that regulates cell contractility and actin stress fiber formation [34]. I
co-administered sorafenib with a ROCK inhibitor (Y27632) in both the 231 and SkBr3
cell lines on the collagen-rich ECM (Figures 4.7E-F). When compared to the sorafenib
alone condition (black lines), ROCK inhibition (red lines) dampened sorafenib resistance
across all moduli, except for the stiffest condition; however, even in the presence of
ROCK inhibitor, the IC-50s still increased with stiffness in both cell lines. Going further,
I attempted to block cell adhesion to the collagen-rich ECM by co-administering
sorafenib with a blocking antibody to the β1 integrin subunit (blue lines). Blocking β1
integrin was significantly effective in the 231 cells at all stiffnesses, but had no effect on
sorafenib resistance in the SkBr3s, perhaps implying that SkBr3s can survive sorafenib
treatment in low adhesive environments. Finally, I treated cells with an inhibitor to
EGFR, given the known role EGFR activation in promoting resistance of several HCC
cell lines to sorafenib [35], and given the fact that all these experiments are supplemented
with EGF. EGFR inhibition (green lines) increased the efficacy of sorafenib modestly in
both cell lines, but the trend of stiffness-induced drug resistance remained. Taken
together, neither ROCK nor EGFR appears to regulate stiffness-mediated sorafenib
resistance; however, β1 integrin antibody may be a candidate for co-treatment with
sorafenib in triple negative breast cancer (the subtype of the 231 cell line), but not HER2
overexpressing breast cancer (SkBr3 subtype).
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4.4.3 Signaling pathways activated during ECM stiffening
Given that β1 integrin antibody was the only effective co-treatment with sorafenib
in the 231 cells, I investigated a subset of candidate signaling pathways, downstream of
β1, which might be interfering with sorafenib efficacy. I used a multi-plex MAGPix
system to quantify the phosphorylation of three members of the MAPK family (ERK1/2,
JNK, p38), and Akt of the PI3K pathway at multiple time points post-adhesion to the
softest and stiffest substrates tested in the 231 cell line (Figures 4.8A-D). On both the
collagen-rich and basement membrane ECMs, I observed an early peak in
phosphorylation of ERK1/2 and Akt post-adhesion, but there was no difference when
comparing between the soft and stiff gel conditions. JNK phosphorylation was delayed
on the basement membrane ECM when compared to the collagen rich ECM, and the
activity of JNK and p38 was higher on the stiffer gel at all time points on the collagenrich ECM. Therefore, changes in JNK signaling could partially explain differences in cell
behavior on the two protein mixtures, and both JNK and p38 are promising candidates to
explain sorafenib resistance on stiff substrates.
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Figure 4.8 JNK and p38 phosphorylation increases on stiff substrates. Phosphorylation levels of ERK1/2 (A) and Akt (B)
over time (x-axis) as cells adhered to the gel surface are not sensitive to the change in stiffness (red = 6kPa, blue = 400kPa) for
both collagen-rich (top row) and basement membrane (bottom row) ECMs, as determined by a MAGPix assay. (C) JNK activity is
higher on the stiff substrate with both protein mixtures, and p38 phosphorylation (D) is higher on the stiff substrate on the
collagen-rich ECM. Statistics are with respect to the soft gel condition at the same time point. N ≥ 2 independent biological
replicates, and N = 3 technical replicates. Figure adapted with permission from [74]. © 2014 Elsevier, Inc.

4.4.4 Combinatorial treatment of a JNK inhibitor and sorafenib on stiff substrates
To determine whether sorafenib treatment perturbed the activity of these signaling
proteins, I allowed 231 cells to adhere to the two stiffness gels coupled with collagen-rich
ECM for 24 hours, and performed the MAGPix assay at various time points directly
following a 15 µM sorafenib treatment. Upon sorafenib treatment, ERK1/2
phosphorylation on the stiff substrate remained significantly higher than that on the softer
gel at early time points post-dosing (Figure 4.9A). Akt phosphorylation also peaked in
the first hour after sorafenib treatment; however, there was no difference in Akt
phosphorylation between the soft and stiff substrates, which further confirmed that Akt
signaling was not involved in stiffness-mediated drug resistance (Figure 4.9B). The
observed peak in Akt might be due to the ability of Ras to mediate signaling through
PI3K/Akt pathway [36], while sorafenib inhibits the Ras/Raf/MEK/ERK pathway. JNK
phosphorylation was highest on the stiff substrate, and, unlike ERK and Akt, did not
change over time (Figure 4.9C). Sorafenib treatment also reduced the stiffness sensitivity
of p38 phosphorylation (Figure 4.9D).
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Figure 4.9 Stiffness-induced sorafenib resistance is mediated by JNK activity. 231
cells on collagen-rich ECM were treated with 15 µM sorafenib, and subsequent
phosphorylation of ERK1/2, Akt, JNK, and p38 was quantified with a MAGPix assay.
(A) ERK phosphorylation remained high on stiffer substrate (blue) at early time points
(x-axis) when treated with sorafenib. (B) Akt phosphorylation peaked at 1 hour postsorafenib treatment, but did not vary with stiffness. (C) Sustained phosphorylation of
JNK was unaffected by sorafenib treatment, and high levels were maintained on the stiff
substrate. (D) Phosphorylation of p38 in the presence of sorafenib was not significantly
different between soft and stiff substrates. N ≥ 2 independent biological replicates, and N
= 3 technical replicates. Statistics are relative to the soft gel condition. Figure adapted
with permission from [74]. © 2014 Elsevier, Inc.
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Figure 4.10 Co-administering sorafenib with a JNK inhibitor reduces the stiffnessinduced drug resistance. (A) MTS assays were performed on 231 cells on collagen-rich
ECM in the presence of sorafenib alone (black), sorafenib plus a pharmacological JNK
inhibitor (blue, SP600125), sorafenib plus an ERK inhibitor (red, FR18204), or sorafenib
plus p38 inhibitor (yellow, BIRB796). The sorafenib dose was varied (resulting in an IC50, y-axis), while inhibitor concentrations were constant. JNK inhibition reduced both the
overall sorafenib resistance and stiffness-induced resistance (compare the blue and black
lines), whereas p38 and ERK inhibitors did not affect sorafenib efficacy. (B) Combining
either ERK (purple) or p38 (green) inhibitors with JNK inhibitor and sorafenib reversed
the previously observed effect of inhibiting JNK alone (blue). N ≥ 3 independent
biological replicates, and N = 3 technical replicates. Statistics are relative to the soft gel
condition. Figure adapted with permission from [74]. © 2014 Elsevier, Inc.
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When considering the results in Figures 4.8 and 4.9 together, ERK, p38, and JNK
were all potential candidates for involvement in stiffness-mediated sorafenib resistance. I
co-administered sorafenib with inhibitors to each of these molecules (Figure 4.10A), and
found that JNK inhibition (blue line) both significantly increased sorafenib efficacy, and
eliminated the impact of substrate stiffness. In hindsight, this result could have been
anticipated, as JNK was the only signaling molecule both enhanced by substrate stiffness
during cell adhesion (Figure 4.8C), and unaffected by sorafenib treatment (Figure 4.9C).
With an expected synergistic effect in mind, I then co-administered sorafenib with JNK
inhibitor, and either ERK or p38 inhibitors (Figure 4.10B). Strikingly, I found that
combining either p38 or ERK inhibitors alongside the JNK inhibitor and sorafenib
treatment reversed the effect of co-administering the JNK inhibitor alone.
4.4.5 Enrichment of mammary stem/progenitor cells on stiff substrates
Cancer

stem/progenitor

cells

(CSC)

are

notoriously

resistant

to

chemotherapeutics, and exposure to chemotherapy can lead to an increase of CSCs
population [37]. The stemness of cancer cells was also found to be modulated by the
tumor microenvironment in colon cancer [38]. Therefore, I investigated whether the
observed drug resistance on stiffer substrates could be caused by an increase in the CSC
population. Since let-7 microRNAs are present in differentiated cells, but depleted in
mammary progenitor cells [39], MDA-MB-231s expressing DsRed-let7c-sensor were
cultured on varying-modulus gels, which were coupled with collagen-rich proteins, for 7
days. The number of DsRed expressing cells were observed to increase over time,
indicating an increase in the number of progenitor cells, but there was not any difference
across stiffnesses (Figure 4.11). The increase in progenitor cells could be due to an
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increase in the total cell population, as the cells were proliferating. To be more precise,
flow cytometry was performed to quantitatively measure the fraction of the DsRed
population (Figures 4.12A-F). The fraction of DsRed cells were similar across all
stiffnesses, and accounted for approximately 0.2% of the entire population. Thus it can be
concluded that the stiffness-induced sorafenib resistance was not caused by an increase in
number of progenitor cells on stiff substrates.
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Figure 4.11 The number of progenitor cells over time. The total number of mammary
stem/progenitor cells increases over time, but not regulated by substrate modulus.
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Figure 4.12 The enrichment of mammary stem/progenitor cells are independent of
substrate modulus. (A) non-DsRed expressing cells were used as a negative control. (B)
DsRed expressing cells were used as a positive control. An increase in substrate modulus
with (C) 23kPa, (D) 165 kPa, and (E) 400 kPa does not significantly change the
population of stem/progenitor cells (F). Abbreviations: SSC-A: side scatter-area.
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4.5 Discussion
Several groups have demonstrated a link between substrate stiffness and cell
proliferation across a variety of cell types [26, 40-43], and many of these studies have
linked stiffness sensing, the actin and microtubule cytoskeleton, and the classic RhoROCK pathway. This foundation of work has propelled me and others to determine if this
pathway, which is known to control cell growth and survival, might also be responsible
for drug resistance in stiff tumor environments. For instance, Zustiak et al found that
paclitaxel, a cytotoxic microtubule stabilizing agent, eliminated stiffness-induced drug
resistance in most tested cell lines [26]. However, chemotherapies that induce apoptosis
via non-cytoskeletal pathways, are also affected by substrate stiffness. Schrader et al.
showed that stiff substrates reduced HCC cell apoptosis when treated with cisplatin,
which causes apoptosis by crosslinking cellular DNA [25]. These studies motivated me
to look at how stiffness might perturb the efficacy of a common chemotherapeutic within
another class of drugs, specifically, sorafenib, a Raf kinase inhibitor that targets the
Raf/MEK/ERK pathway. I also observed a clear stiffness-induced resistance to sorafenib
across multiple cell lines. Consistent with Schrader et al., the HCC cell line (HEP3B) was
the most stiffness-sensitive cell line tested, and showed a positive correlation between
cell proliferation (at 24 hours) and drug resistance (Figure 4.6A). However, cell
proliferation did not correlate with drug resistance in any of the other cell lines tested,
which were all from breast carcinoma; thus the simplest explanation for the results in
Figure 4.4, that cell proliferation on high stiffnesses was responsible for sorafenib
resistance, does not hold. The IC-50s for most cell lines are higher on collagen-rich
proteins than on basement membrane proteins, with the exception of the SkBr3 cell line,
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which has similar IC-50s on both protein mixtures (Figure 4.4A-B). Yang et al. also
found that binding of SkBr3 cells to laminin, which is a component in the basement
membrane mixture, causes substantial resistance to anti-ErbB2 agents [11], possibly
agreeing with the results in the SkBr3 cells. These results point to maximum possible
sorafenib resistance in stiff, collagen-rich microenvironments, which represent highly
progressed tumors. These results implicate tumor stiffening as a cause for the lack of
success for sorafenib, which boasts a paltry 3-month survival increase in comparison to
placebo in HCC [29].
Integrin binding can mediate cellular responses to substrate stiffness via RhoA
activity, leading to stress fiber formation, focal adhesion assembly, actomyosin
contractility, and cell spreading [34, 44, 45]. Although I did observe cell spread area
changes in response to both stiffness and ECM protein (Figure 4.7A-D), I quantified no
change in stiffness-induced resistance trend when co-administered sorafenib with ROCK
inhibitor. Instead, I examined whether integrin-binding mediated this stiffness-induced
drug response via some other pathway. β1 integrin has a high affinity for collagen [46],
and increased signaling through β1 integrin binding protects cancer cells (MDA-MB-231
and MDA-MB-435) against paclitaxel [8] and small cell lung cancer cells against
doxorubicin, cyclophosphamide, and etoposide [47]. Reducing β1 integrin binding with
an antibody sensitized the 231 cells to sorafenib, but did not affect the SkBr3s (Figure
4.7E-F). Park et al. also observed that SkBr3 cells were not responsive to β1 integrin
inhibition as compared to MDA-MB-231, likely because of their inherently low β1
integrin expression [9].
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Ezzoukhry et al. observed that inhibiting EGFR sensitized several HCC cell lines
to sorafenib treatment [35]; however, I found that co-treatment of a pharmacological
EGFR inhibitor with sorafenib in both MDA-MB-231 and SkBr3 cells only affected
sorafenib efficacy on soft gels (Figure 4.7E-F). Given that integrin binding to the ECM
can enhance EGFR phosphorylation in the absence of ligand binding [48], it is possible
that, at lower stiffnesses, β1 integrin predominantly mediates signaling through EGFR
phosphorylation in the absence of ligand binding [49], but not at higher stiffness.
I found that JNK was the key mediator of sorafenib resistance on stiff substrates
(Figures 4.8-4.10). Activation of JNK has been reported to mediate either pro-apoptotic
or anti-apoptotic signaling pathways depending on stimuli [50, 51], with parallel
contradictory roles in vivo, either supporting tumor growth [52-55] or suppressing
tumorigenesis [56-59]. My results indicate a role for JNK in enhancing cell survival
during sorafenib treatment, and for the first time I show that JNK activation is regulated
by substrate stiffness. The high activity of JNK on stiff substrates implicates high Rac1
activity and low RhoA activity [49, 60], and low RhoA activity is consistent with the
overall lack of stress fiber formation observed in 231 cells [61], regardless of stiffness
(Figure 4.7A). Further, ROCK inhibition did not affect the stiffness-induced drug
resistance. Finally, RhoA/ROCK can activate ERK [28], and indirectly activates PI3KAkt pathway [62], supporting my observations of a lack of stiffness-dependent ERK or
Akt phosphorylation (Figures 4.8A-B).
Conversely, when we quantified phospho-protein activity in the presence of
sorafenib and PDGF and EGF, we observed that ERK phosphorylation was higher on the
stiff substrate. This is consistent with other observations that cells on stiff substrates are
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more sensitive to EGF stimulation in comparison to those on soft substrates (Figures
4.9A-B) [19, 23]. However, this transient ERK activation on stiff substrates did not
prolong cell survival in the presence of sorafenib treatment (Figure 4.10A). Combining
both p38 and JNK inhibitors alongside sorafenib reversed the effect of inhibiting JNK
alone, suggesting negative crosstalk between JNK and p38. Other studies have reported
this antagonism between p38 and JNK before [63, 64]. I observed this same rescue of
stiffness-mediated sorafenib resistance when I co-administered JNK and ERK inhibitors,
which is also supported by reports of JNK and ERK antagonism [65, 66].
Overall, these results elucidate a role for JNK in mediating resistance to sorafenib
through β1 integrin binding to collagen-rich environments (Figure 4.13). β1 integrin
activation leads to Src-mediated phosphorylation of EGFR [49, 67], which activates
Ras/Raf/MEK/ERK and PI3K/Vav2/Rac1/JNK. Inhibiting EGFR improved the efficacy
of sorafenib on soft gels (Figure 4.7E), which I attribute to low β1 integrin affinity [49].
At high stiffness, however, EGFR inhibition had no effect, as integrin clustering
increases, recruiting the FAK-Cas complex and activating Ras/Rac1/JNK [68-70].
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Figure 4.13 Proposed role for JNK in stiffness-mediated sorafenib resistance. I
propose that stiff gels increase β1 clustering when bound to ECM, increasing the
activation of the Ras-Raf-MEK pathways, which is targeted by sorafenib, but also Rac1
and downstream JNK activation, offering increased cell proliferation and anti-apoptosis
signaling, protecting cells from sorafenib. Inhibiting ERK and p38 are known to block
JNK inhibition, providing a reversal of the observed ability of JNK inhibition to improve
sorafenib efficacy on stiff substrates. Blue boxes indicate the microenvironment changes
that are controlled, green boxes indicate the biological responses that are measured, and
red letters indicates inhibitors used to perturb the signaling pathways. Figure adapted
with permission from [74]. © 2014 Elsevier, Inc.
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In sum, the ability to capture the cell-matrix interactions present in the in vivo
tumor microenvironment could profoundly influence our ability to understand true drug
efficacy in vitro. Others have created similar high-throughput biomaterial platforms
including ECM microarrays [71], contact-printed microarrays [72], PEG microwells [73],
and 2D biomaterials in 96-well plates [26, 41]. The most promising of these approaches
have each used polyacryamide (PAA) gels, but require either a complicated plate insert
[41], or manually placing gels into individual wells [26]. My method of casting PEG-PC
gels allowed me to quickly make multiple uniform gels of varying stiffnesses in multiple
96-well plates at the same time, and does not require fabrication of any special devices
(Figure 4.2). My high-throughput PEG-PC platform allowed me to identify β1 integrin,
and its downstream effector, JNK, as mediators of tissue stiffening-induced drug
resistance. Co-administering sorafenib with inhibitors to either of these targets equally
eliminated stiffness-induced resistance in the 231 cells (Figure 4.14). However, when coadministering sorafenib with inhibitor to JNK, p38, and ERK in SkbR3 cells, the IC-50s
were dampend, but the stiffness-induced drug resistance trend remained (Figure 4.15).
This results were further supported with the measurement of phosphorylation levels of
these molecules on soft and stiff substrates (Figure 4.16).
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Figure 4.14 Inhibition of JNK shows similar results to treating with a β1 integrin
antibody. Inhibition of β1 integrin or its downstream effector JNK reduces the overall
IC-50 and eliminates the stiffness-mediated drug resistance trend. Statistics shown are
with respect to the softest gel condition. Figure adapted with permission from [74]. ©
2014 Elsevier, Inc.
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Figure 4.15 Inhibitions of JNK, ERK, and p38 do not dampen the stiffness induced
drug resistance in SkBr3 cells. Inhibition of these molecule enhance the effectiveness
of sorafenib at all conditions, but does not eliminate the stiffness-induced sorafenib
resistance.
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Figure 4.16 SkBr3s' Akt phosphorylation is increased on stiff subtrate. (B) Akt is the
only signaling molecule that shows a modest increase in phosphorylation on stiff gels
whereas the phosphorylation of (A) ERK, (C) JNK, (D) p38 are similar between soft and
stiff substrates.
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4.6 Conclusions
I propose that systems like my high-throughput PEG-PC hydrogel platform are
critical for future screening of potential chemotherapeutics, as well as for discovery of
possible mechanisms for failed efficacy of previously promising targets. With my
platform, I discovered that the efficacy of sorafenib in carcinoma could potentially be
increased by co-administering inhibitors to β1 integrin or JNK, which could not have
been appreciated on traditional tissue culture plastic plates. My results highlight the
importance of incorporating relevant tissue stiffness and integrin binding ligands into the
high-throughput drug screening process to increase the success of drugs in the
development pipeline.
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CHAPTER 5

A COMPARISON BETWEEN 2D AND 3D PLATFORMS FOR CANCER
DRUG SCREENING

5.1 Abstract
The tumor microenvironment plays an important role in providing a niche to
nurture tumor growth and promote drug resistance. Various platforms have been
developed to recapitulate many key features of the tumor ECM. I have taken a holistic
approach to compare the drug response of the MDA-MB-231, an EGFR overexpressing
cell line, and SkBr3, a HER2 overexpressing cell line, across different types of two and
three dimensional (2D and 3D) platforms. I have tested sorafenib (a Raf inhibitor),
lapatinib (an EGFR/HER2 inhibitor), temsirolimus (a mTOR inhibitor), and doxorubicin
(a cytotoxic drug), and observed that the sensitivity of cell-drug interaction to
microenvironment is dependent on both drug type and cell type. The IC-50s of SkBr3s
when treated with sorafenib and temsirolimus were most sensitive to the change in
platform, whereas those of 231s were sensitive to the platform type when treated with
sorafenib and lapatinib. The IC-50 of both cell lines, when treated with doxorubicin, were
not sensitive to the type of platform. Both HER3 and EGFR phosphorylation in SkBr3s
were found to be sensitive to the change in the surrounding microenvironment whereas
HER2 phosphorylation was not. Long-term culture of SkBr3 cells with lapatinib induced
an upregulation of Insulin Receptor (IR) and its downstream effector ERK in 2D, but not
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in 3D. These results provide insights into how the interaction between cell and
microenvironment influences their response to drug and may guide future development of
biomaterial platforms for drug screening.

5.2 Introduction
Many groups have developed various cell culture platforms in both 2D and 3D
that are capable of capturing the key features of the tumor microenvironment to study
cellular response to chemotherapeutics. For example, I have previously developed a highthrough put drug screening tool based on PEG-PC hydrogel system, whereas others have
done so with PAA hydrogels [1,2], and all of these systems can be easily integrated with
the traditional high-throughput screening of drug compounds in 96- or 384-well plates.
Other high-throughput systems, which are more complicated to fabricate, have also been
developed such as PEG microwells [3] and microarray for cell-based drug screening [4].
In addition, cell-drug interaction can be studied in 3D biomaterial scaffolds such as PEGbased hydrogels that encapsulated single cell [5] or spheroids [6,7], or gelatin hydrogel
encapsulating spheroids [8]. Other 3D spheroid models include various methods that
induce spheroid formation through allowing aggregation of non-adherent cells such as
agarose [9] or PDMS [10] coated plates.
Each type of these models has advantages and drawbacks with respect to
recapitulation of the complex biology, ease of fabrication and use, cost, etc. As compared
with 3D models, the 2D platforms are easier to fabricate and scale up for high-throughput
screening; however, these models can only capture the tissue mechanical properties and
allow highly-controlled bioconjugation of integrin binding sites. They cannot recapitulate
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the 3D microenvironment that cells experience in vivo. Some 3D models can capture the
three dimensional geometry, modulus, integrin binding sites, and MMP degradable sites
that allow cells to remodel the environment. For instance, Leight et al. developed a 3D
PEG-based platform with MMP-degradable and MMP sensor peptides to study the
relationship between RAF inhibitors and MMP activity of metastatic melanoma cells [5].
However, single cells encapsulated in these 3D materials lack the in vivo cell-cell contact.
Cadherins, which mediate cell-cell contact, can crosstalk with other growth factors
receptors such as EGFR [11], HGFR, and FGFR [12] followed by activation of
downstream signaling pathways such as Wnt signaling [12] or MAPK [13] that can
promote survival in the presence of chemotherapeutics [14]. Thus, the spheroid models
allow cells to establish complex cell-cell and cell matrix interactions and capture certain
features of human in vivo tissues such as histomorphology, function, and
microenvironments [15]; therefore, they are usually touted as an ideal model for
preanimal and preclinical drug screening to identify promising drug candidates [9].
However, it takes time for spheroid culture, and it is also hard to scale-up for highthroughput screening.
To identify an appropriate model for drug screening, I investigated cell-drug
interaction across multiple platforms: the common tissue culture plastic plate, 2D
hydrogel platform, 3D platform that encapsulates single cell or spheroid. Since variation
in modulus is known to affect cellular response to drugs [1,16,17], I considered two
different moduli for each platform. I applied the previously developed 2D PEG-PC
platform [16,18] and the 3D PEG-Maleimide (PEG-MAL) system, which is wellcharacterized by Phelps et al. [19]. PEG-MAL can be crosslinked by thiol containing
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crosslinker following Micheal-type addition, which requires a nucleophilic buffering
reagent such as TEOA or HEPES instead of using toxic free-radicals and UV light [19]. I
tested 3 targeted drugs, which target the two most common cell proliferation pathways
(temsirolimus - Akt/mTOR and sorafenib - Raf/MEK/ERK) and two of the most wellcharacterized receptor tyrosine kinases (lapatinib - EGFR and HER2), and one cytotoxic
drug (doxorubicin). I also examined the sensitivity of RTK receptors to modulus in 3D
under growth factor stimulation and the influence of 2D and 3D platforms to RTKs'
phosphorylation and downstream signaling in drug-treated cells.

5.3 Materials And Methods
5.3.1 Cell culture
All supplies were purchased from Life Technologies (Carlsbad, CA) unless
otherwise noted. Human breast cancer cell lines (MDA-MB-231 and SkBr3) were
generous gifts from Dr. Shannon Hughes at the Massachusetts Institute of Technology,
and were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) at 37ºC and 5%
CO2.
5.3.2 Spheroids culture
The lyophilized poly(N-isopropylacryamide)-poly(ethylene glycol) (PNIPAAmPEG, Cosmo Bio, Carlsbad, CA) was reconstituted in cell culture medium for a day and
kept in the refrigerator for long-term storage. All cell suspensions were prepared at a
density between 1-1.5 million cells per mL. An appropriate volume of cell suspension
was added into PNIPAAm-PEG solutions to make 100,000 cells/mL for SkBr3s and
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167,000 cells/mL for 231s. The gel solution was kept on ice to prevent early gelation.
Gels with 150 μL volume were pipetted into a 6-well plate, and the plates were incubated
in the incubator for 10-15 minutes to induce gelation. After gelation, cell culture medium
was added to the wells. Cells were cultured to grow into spheroids for 14 days, and the
medium was replenished every other day.
5.3.3 Hydrogel mechanical characterization
Hydrogels polymerized from 4-arm PEG-maleimide (20 kDa, PEG-MAL, Jenkem
Technology USA, Plano, TX) were used as a platform to study the response of cells to
drugs in 3D. PEG-MAL solutions were prepared at 10 wt % and 20 wt %, and PEG
dithiol (average Mn 1000, Sigma-Aldrich, St. Louis, MO) was dissolved in
triethanolamine (TEA, pH ~ 7.4) at concentrations of 100 and 200 mg/mL.
Polymerization of PEG-MAL gels were induced by combining 10 and 20 wt % PEGMAL with 100 and 200 mg/mL of PEG dithiol, respectively (9:1 PEG-MAL:PEG dithiol
by volume). Hydrogel cylinders for mechanical compression testing were formed in 5mm Teflon molds and swelled in PBS for 24 h. Post swelling, hydrogel dimensions were
measured with a digital caliper, and mechanical compression tests were performed with a
TA Instruments (New Castle, DE) AR-2000 rheometer at a 2 μm/s strain rate. The
Young’s modulus (E) for each hydrogel was calculated by plotting the measured normal
force between 0 and 4% strain and dividing the slope of the best-fit linear regression by
the hydrogel cross-sectional area.
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5.3.4 Quantification of drug response
5.3.4.1 Spheroids in 3D PEG-MAL hydrogels
The medium in the 6-well plate that had spheroids cultured in PNIPAAm-PEG
was removed. 4 mL of cold serum-free DMEM supplemented with 1% pen/strep were
added to each of the well, and the plate was kept on ice for 5 minutes to ensure the
complete dissolution of PNIPAAm gels. The spheroids in suspension were transferred
into 2 15-mL tubes with equal volume in each, and cut pipette tips were used to handle
the spheroids in order to reduce the shear stress. The tubes were kept on ice for 30
minutes to allow the spheroids to settle at the bottom. After 30 minutes, the medium was
carefully removed so that the spheroids were not disturbed. Then the spheroids in each
tube were resuspended in 10 wt % and 20 wt % PEG-MAL dissolved in serum-free
DMEM. Cell binding peptide CRGD (Genscript, Piscataway, NJ) was added to the PEGMAL solutions to make 2 mM final concentration. The gels were made in a 48-well plate
by combining 9 μL of PEG-MAL with 1 µL of PEG dithiol in TEOA. The gel was
allowed to polymerize for 5 minutes before addition of either serum-free DMEM
supplemented with 1% P/S, 20 ng/mL of epidermal growth factor (EGF, R&D Systems,
Minneapolis, MN) and 20 ng/mL of platelet-derived growth factor (PDGF-BB,
eBioscience, San Diego, CA) or DMEM with 1% P/S and 10% FBS. To ensure the
consistency among experiments, the amount of spheroids collected from 1 PNIPAAm
gels were consistently transfered to 9 PEG-MAL gels. After 24 h, spheroids were treated
with lapatinib (0-80 μM, LC Laboratories, Woburn, MA), sorafenib (0-64 μM, LC
Laboratories), temsirolimus (0-80 μM, Selleckchem, Houston, TX), or doxorubicin (0-20
μM, LC Laboratories). All drugs were dissolved in the same type of medium as the
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spheroids prior to drug treatment. Dimethyl sulfoxide (DMSO, Sigma-Aldrich) was used
as a vehicle control in all experiments. After 48 h of drug treatment, cell viability was
quantified by CellTiter Glo® Luminescent Cell Viability Assay (Promega, Madison,
WI), which measured the amount of ATP in the cells. After 40 minutes of incubation, the
plate were read with the Synergy 2 Multi-Mode Reader (BioTek, Winooski, VT). The IC50s were calculated by using the Excel's non-linear curve fitting of the data.
5.3.4.2 Single cells in 3D PEG-MAL hydrogels
Cells cultured on tissue culture flask were collected and resuspended in PEGMAL solutions at the concentration of 555,556 cells/mL (5,000 cells per gel). PEG-MAL
gels including 2 mM RGD were made as described above and kept in serum-free DMEM
with growth factors. After 24 h, the cells were treated with similar drugs described above.
5.3.4.3 Cells on 2D PEG-PC hydrogels
2D PEG-PC hydrogels in the 96-well plate and protein coupling were prepared as
described previously [16]. PC was used at 17 wt % (0.6M), and PEG was used at 1.1 wt
% (0.015 M) and 3.2 wt % (0.043 M) to make 10 and 33 kPa gels, respectively. Collagen
I was coupled to the gel surface at 3.3 μg/cm2. Cells were seeded at 10,000 cells per well
in serum-free DMEM with growth factors. After 24 h, the cells were treated with similar
drugs described above.
5.3.4.4 Cells on tissue culture plastic plate
Cells were seeded at 5,000 cells per well in serum containing medium. After 24 h,
the medium was replaced with serum-free medium supplemented with EGF and PDGF
growth factors. After 24 h, cells were treated with similar drugs.
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5.3.5 Quantification of cell number in spheroids in PEG-MAL gels
In order to quantify the total number of cells in each of the PEG-MAL gel
encapsulating spheroids, the total amount of DNA in spheroids was quantified with
CyQUANT Cell Proliferation Assay Kit (Life Technologies). The assay was prepared by
mixing the 1X cell lysis buffer with the Cyquant GR Dye (1:400, Dye:Lysis buffer). The
gels were removed from the plate with a spatula and placed in 1.5 mL microcentrifuge
tubes. All tubes were flash-frozen with liquid nitrogen. 200 μL of the assay were added to
the tube. The hand-held biovortexer (Research Products International, Mt Prospect, IL)
was used to mechanically break down the gels and enhanced the release of the dye into
the solution. The solutions were transfer to a 96-well plate, and the fluorescent intensity
was read at 480/520 excitation/emission with the Synergy 2 plate reader.
5.3.6 EGF stimulation of spheroids in PEG-MAL gels
Spheroids were encapsulated in 10 and 20 wt % PEG-MAL with RGD binding
peptides and serum-starved for 24 h. Then spheroids were stimulated with 100 ng/mL of
EGF, and cell lysates were collect at 10, 30, and 60 min. After 1 h, EGF medium was
replaced with serum-free medium, and cell lysates were collected at 7 and 24 h time
points. Cell lysis buffer (MILLIPLEX® MAP Phospho Mitogenesis RTK Magnetic
Bead, EMD Millipore, Billerica, MA) was supplemented with protease (EDTA-free
Protease Inhibitor Cocktail Tablets, 1 tablet in 3 mL, Roche, Indianapolis, IN) and
phosphatase (2x phosphatase inhibitors cocktail-II, Boston Bioproducts, Boston, MA)
inhibitors, 1 mM of phenylmethylsulfonyl fluoride (PMSF, Thermo Scientiﬁc, Rockford,
IL), 5 μg/mL of pepstatin (Thermo Fisher Scientiﬁc, Waltham, MA), 10 μg/mL of
leupeptin (Thermo Fisher Scientiﬁc), 1 mM of sodium pyrophosphate (Thermo Fisher
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Scientiﬁc), 25 mM of β-glycerophosphate (Santa Cruz, Dallas, TX), 1 mM of sodium
orthovanadate (MP Biomedicals, Solon, OH). At each time point, the gels were washed
with ice-cold 1X PBS, transfered to the tubes, frozen with liquid nitrogen, and stored at 80ºC. Multiple gels were combined in order to collect enough proteins for each of the
condition. When collecting lysates, samples were allowed to thaw on ice for 20 minutes
before addition of cell lysis buffer. A biovortexer was used to enhance the release of the
proteins to the solution. Total protein concentration was quantified with a BCA protein
assay (Thermo Scientific). Lysate concentrations were adjusted to 120 μg/mL, and the
phosphorylation levels of c-MET/HGFR, EGFR, ErbB2/HER2, ErbB3/HER3,
ErbB4/HER4, IGF-1R, IR were quantified with a MAGPIX (Luminex, Austin, TX) with
the MILLIPLEX® MAP Phospho Mitogenesis RTK Magnetic Bead (EMD Millipore)
according to the manufacturer instructions.
5.3.7 Long-term lapatinib treatment on 2D and in 3D
SkBr3 single cells were either encapsulated in PNIPAAm-PEG gels or seeded on
a plastic 6-well plate. Post encapsulation/seeding, cells were kept in cell culture medium
with either 1.25 μM of Lapatinib or DMSO control. After 14 days, both cells on plastic
plate and in gels were serum-starved for 24 h. Then cells were stimulated with 10%
serum medium for 15 min, and cell lysates were collected. The phosphorylation levels of
similar RTKs and downstream signaling molecules (ERK1/2, Akt, JNK, Bio-Plex Pro™
phospho-ERK1/2, phospho-Akt, phospho-JNK, Bio-Rad Laboratories, Hercules, CA)
were quantified.
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5.3.8 Statistical Analysis
Prism v5.04 (GraphPad Software) was used to perform unpaired Student's t-test, a
one-way analysis of variance (ANOVA) with a Tukey post-test, and a two-way ANOVA.
Data are reported as mean ± standard error. p ≤ 0.05 is denoted with *, ≤ 0.01 with **,
and ≤ 0.001 with ***; P > 0.05 is considered not significant (“ns”).

5.4 Results
5.4.1 The influence of platform to the IC-50 is drug-type dependent
I have evaluated drug response across 4 different classes of drugs with two cell
lines on classic plastic surfaces, 2D gel surfaces, and within 3D gels (either as single cells
or spheroids in serum or serum-free medium) to identify the appropriate model for each
type of drug mechanism (Figure 5.1A). The drugs include sorafenib, which targets Raf
kinase in the Raf/MEK/ERK pathway, lapatinib, which targets EGFR/HER2 receptor
tyrosine kinases (RTK), temsirolimus, which targets mTOR in the PK3K/Akt pathway,
and doxorubicin, which causes cell death by DNA intercalation. All of the experiments
were done with serum-free DMEM supplemented with P/S and 20 ng/mL of EGF and
PDGF except for some experiments with spheroid in 10% FBS medium as indicated. For
3D platform, single cells were encapsulated in PNIPAAm-PEG hydrogels and cultured
for 14 days to induce spheroid formation (Figure 5.1B-E). Spheroids were then
transferred to PEG-MAL gels of 10 and 20 wt. %, which were measured to be 3 and 5
kPa (Figure 5.2). The similar fluorescent signals, which were determined by the
fluorescent DNA-binding dye, between 3 and 5 kPa PEG-MAL gels indicate that the total
amount of spheroids were evenly distributed (Figure 5.3).
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Figure 5.1 Schematic of different types of platforms for drug screening. (A) Cells
were laid on polystyrene 96-well plates and PEG-PC gels of different stiffnesses in 96well plate, or encapsulated in PEG-MAL gels of different stiffnesses as single cells or
spheroids. Spheroids were treated with either serum medium or no-serum medium. Scale
bars are 100 μm. Representative images of SkBr3 cells encapsulated in PNIPAAm-PEG
hydrogel on day 1 (B) - (C) and day 14 (D) - (E).
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Figure 5.3 The amount of spheroids are similar between 3 and 5 kPa PEG-MAL
gels. (A) The fluorescent intensity, which correlates with the amount of DNA, are the
same. (B) The fluorescent intensity is linearly correlated with cell number.
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Drug resistance in spheroids can be mediated by the limitation of drug diffusion
into the spheroids [20], and drug and oxygen diffusion can decrease significantly for
tumor cells that were more than 60 μm from blood vessels [21]. Therefore, all spheroids
were harvested when their size were around 100-150 μm in diameter (Figure 5.1E) to
eliminate this possibility. For both cell lines, proliferation was quantified at the same time
point as drug treatment. When analyzing the proliferation of SkBr3 across all platforms,
the students' t-test, which was used to compare the proliferation between soft and stiff
gels within the same platform, shows a significant increase in proliferation of monolayer
cells on stiff 2D PEG-PC gels and a decrease in proliferation of single cell and spheroids
in stiff 3D PEG-MAL gels as compared with the other modulus condition (Figure 5.4A).
This observed opposite trend in proliferation between 2D and 3D platforms is consistent
with other observations that cells proliferate more on 2D stiffer substrate [22,23] and in
3D softer gels [24,25]. When comparing between 2D and 3D platforms (2D gels, 3D
single cell and spheroids), two-way ANOVA analysis found that the change in platform
was the larger driver of proliferation (35% of total variance, p < 0.0001), followed by
modulus (10%, p < 0.0001) (Table 5.1). Proliferation on plastic could not be included in
two-way ANOVA analysis because it had only one stiffness condition. When comparing
the effect between medium and modulus (3D spheroids with and without FBS), two-way
ANOVA analysis showed that the change in medium had a larger effect on total variance
(56%, p < 0.0001)) than the change in modulus (3%, p = 0.064). When two-way ANOVA
analysis was performed to the IC-50s of all 4 drugs in the same manner with proliferation
data, both sorafenib (Figure 5.4B) and temsirolimus (Figure 5.4D) are strongly sensitive
to platform (51% (p = 0.0018) and 80% (p = 0.0007) of total variance as opposed to 3%
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(p = 0.2898 and 0.2404) from modulus for both sorafenib and tesmirolimus, respectively)
and medium condition (81% (p < 0.0001)and 87% (p = 0.0006) of total variance as
opposed to 2% (p = 0.168) and 0.3% (p = 0.7101) from modulus for sorafenib and
temsirolimus, respectively). For both lapatinib (Figure 5.4C) and doxorubicin (Figure
5.4E), although none of these three variables cause a significant difference in the IC-50s,
the platform was found to affect the results more than modulus (35% (p = 0.0995) vs.
10% (p = 0.2241) and 8% (p = 0.6956) vs. 2 % (p = 0.6735) of total variance for lapatinib
and doxorubicin, respectively). Similarly, medium effected to results more than modulus
(28% (p = 0.1688) vs. 0.08% (p = 0.9351) and 49% (p = 0.0526) vs. 0.01% (p = 0.9764)
of total variance for lapatinib and doxorubicin, respectively). Overall, variations in
platform and medium strongly affected how SkBr3s responded to sorafenib and
temsirolimus, but not to lapatinib and doxorubicin. In addition, when one-way ANOVA
was performed to compared the IC-50s across all conditions for all 4 drugs, spheroids in
serum-supplemented medium were found to be most resistant to sorafenib and
temsirolimus, but not to lapatinib and doxorubicin. Surprisingly, all variations with IC50s across all conditions were not correlated with proliferation (Figures 5.5A-D).
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Figure 5.4 The responses of SkBr3 cells to drugs are dependent on drug types,
platform, and medium condition. (A) The proliferation was quantified across multiple
platforms. The students' t-test showed cells proliferated more on stiffer substrate in 2D
and in softer substrate in 3D. One-way ANOVA analysis across all conditions showed the
IC-50s of spheroids in serum medium were highest with (B) sorafenib and (D)
temsirolimus, but did not change much with (C) lapatinib and (E) doxorubicin.
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Sensitivity to
platform (%)
(2D and 3D)
35 (*)
51 (*)
35
80 (*)
8

Proliferation
Sorafenib
Lapatinib
Temsirolimus
Doxorubicin

Sensitivity to
modulus (%)
(2D and 3D)
10 (*)
3
10
3
2

Sensitivity to
medium (%)
(spheroid only)
57 (*)
81 (*)
28
87 (*)
49

Sensitivity to
modulus (%)
(spheroid only)
3
2
0.08
0.3
0.01

Table 5.1 Two-way ANOVA analysis of SkBr3 cells. Summary of two-way ANOVA
analysis of SkBr3s' IC-50s for sensitivity to platform, medium, and modulus.

A
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30
20

Lapatinib
25

Spearman R = 0.52
p = 0.16

Spearman R = 0.63
p = 0.08

20

IC-50 (µ M)

40

IC-50 (µ M)

B

Sorafenib

10

15
10
5

0

0
0

6000

12000

18000

0

24000

Proliferation (RLU)

15

IC-50 (µ M)

IC-50 (µ M)

18000

24000

Doxorubicin

D

Spearman R = 0.63
p = 0.08

60

12000

Proliferation (RLU)

Temsirolimus

C

6000

40

20

0

Spearman R = -0.52
p = 0.16

10

5

0
0

6000

12000

18000

0

24000

Proliferation (RLU)

6000

12000

18000

24000

Proliferation (RLU)

Figure 5.5 Spearman correlation between IC-50s and proliferation of SkBr3s. There
is not any significant correlation between the IC-50s and proliferation for all drugs: (A)
sorafenib, (B) lapatinib, (C) temsirolimus, and (D) doxorubicin.
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Interestingly, the proliferation of MDA-MB-231 cells also showed a similar
modulus-dependent trend as SkBr3 cells, with cells proliferating more on 2D stiffer gels,
and in 3D softer gels, as indicated by the student's t-test (Figure 5.6A). However, when a
two-way ANOVA was performed as described above, both platform and medium
appeared to affect the proliferation more than modulus (49% (p < 0.0001) vs. 0.8% (p =
0.1329) and 59% (p < 0.0001) vs. 28% (p < 0.0001) of total variance for both platform
and medium, respectively). For sorafenib (Figure 5.6B) and lapatinib (Figure 5.6C),
platform, medium, and modulus significantly contributed to the variation in IC-50s (with
the exception of modulus when compared with platform for sorafenib); however,
platform and medium had a much larger effect on total variance than modulus (Table
5.2). For temsirolimus (Figure 5.6D) and doxorubicin (Figure 5.6E), none of these
parameters significantly affected the outcome of the IC-50; nevertheless, the modulus had
a slightly larger effect on total variance than the platform and medium (with the
exception of modulus when compared with medium for temsirolimus) (Table 5.2). Oneway ANOVA analysis of all IC-50s for 4 drugs indicated that spheroids in serumsupplemented medium were most resistant to sorafenib and lapatinib, but not to
temsirolimus and doxorubicin. Overall, platform, medium, and modulus significantly
affected the 231s' IC-50s of sorafenib and lapatinib, but none of these had any impact on
the IC-50s of temsirolimus and doxorubicin. In contrast to the SkBr3s, the variations in
IC-50s of the 231s were positively correlated with the change in proliferation across
different platforms for sorafenib, lapatinib, and temsirolimus (Figures 5.7A-C); however,
similar to the SkBr3s, there was not a correlation between the IC-50 and proliferation for
doxorubicin (Figure 5.7D).
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Figure 5.6 The responses of MDA-MB-231 cells to drugs are dependent on drug
types, platform, medium, and modulus conditions. (A) The proliferation was
quantified across multiple platforms. The students' t-test showed cells proliferated more
on stiffer substrate in 2D and in softer substrate in 3D. One-way ANOVA analysis across
all conditions showed the IC-50s were strongly sensitive to platform and medium
condition with (B) sorafenib and (C) lapatinib, but did not change much with (D)
temsirolimus and (E) doxorubicin.
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Sensitivity to
platform (%)
(2D and 3D)
49 (*)
91 (*)
76 (*)
11
1

Proliferation
Sorafenib
Lapatinib
Temsirolimus
Doxorubicin

Sensitivity to
modulus (%)
(2D and 3D)
0.8
2
14 (*)
22
11

Sensitivity to
medium (%)
(spheroid only)
59 (*)
96 (*)
86 (*)
22
27

Sensitivity to
modulus (%)
(spheroid only)
28 (*)
2 (*)
9 (*)
10
37

Table 5.2 Two-way ANOVA analysis of MDA-MB-231 cells. Summary of two-way
ANOVA analysis of MDA-MB-231s' IC-50s for sensitivity to platform, medium, and
modulus.
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Figure 5.7 Spearman correlation between IC-50s and proliferation of MDA-MB231s. There is a significant positive correlation between the IC-50s and proliferation for
(A) sorafenib, (B) lapatinib, and (C) temsirolimus, but not with (D) doxorubicin.
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5.4.2 Varying in IC-50 is dictated by cell-microenvironment interaction
Since the change in platform significantly affected how cells responded to certain
types of drug, I quantified the difference in drug response between cells cultured in 3D
and 2D to see if long-term culture in 3D could possibly cause a significant change in cell
behavior that ultimately led to the results above. After 14 days of culture in PNIPAAm,
SkBr3 and MDA-MB-231 spheroids were dissociated, placed on the plastic 96-well plate,
and treated with drugs. The IC-50s were then compared to cells cultured in tissue culture
flasks (Figure 5.8A). Strikingly, only SkBr3 cultured in 3D was 50% more resistant to
sorafenib as opposed to cells cultured in 2D, and the rest of the IC-50s do not show any
significant difference in drug response between cells cultured in 2D and 3D (Figures 5.8B
and C). These results suggested that cell-drug interaction is strongly regulated by the
immediate change in microenvironment/platform not long-term culture condition.
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Figure 5.8 Long-term culture of spheroids in 3D PNIPAAm does not significantly
change the nature of the cells. (A) Cells were cultured to form spheroids for 14 days,
then the spheroids were removed from the gels, dissociated and seeded on the 96-well
plates similarly to cells cultured in the tissue culture flask. Both SkBr3s (B) and MDAMB-231s (C) responded to drugs in a similar manner regardless of culture methods,
except for that SkBr3 cells cultured in 3D were more resistant to sorafenib.
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5.4.3 SkBr3's response to EGF in 3D is independent of stiffness
Cells on stiff 2D substrates were not only more proliferative, but also previously
shown to be more sensitive to EGF stimulation by me [16] and others [26,27]. Since
serum medium contains EGF and many other growth factors, and SkBr3 spheroids
proliferated significantly more in softer gels with serum (Figure 5.4A), I quantified the
response of spheroids to EGF at different stiffness conditions to see if growth factor
stimulation was responsible for the observed difference in proliferation. Encapsulated
SkBr3 spheroids in 3 and 5 kPa gels were stimulated with EGF for an hour, then the EGF
medium was replaced with serum-free medium (Figure 5.9A). The phosphorylation of 7
different RTK receptors (HGFR, EGFR, HER2, HER3, HER4, IGF1R, IR) were
quantified by using a multi-plex MAGPix system; however, only signals from
phosphorylated EGFR, HER2, HER3 were detected. In contrast to observations on 2D
substrates, phosphorylation of EGFR was similar between the two stiffnesses. The
phosphorylation peaked at 10 min after stimulation, then decreased over time (Figure
5.9B). The phosphorylation of HER2 reduced to a minimum at 30 min and 60 min for 3
and 5 kPa gels, respectively (Figure 5.9C). Similar to this trend, the phosphorylation of
HER3 in the 3 kPa gels decreased to a minimum at 60 min and remained low (Figure
5.9D); however, HER3 phosphorylation in the 5 kPa gels did not change significantly
across all time points. Although there were minor differences in phosphorylation of
HER2 at 24 h and HER 3 at 7 h time points, the phosphorylation levels of HER2 and
HER3 across other time points were similar between the soft and stiff gels. When
comparing the phosphorylation of similar RTK receptors between the encapsulated
spheroids in PEG-MAL gel and the unencapsulated spheroids, only signals from
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phosphorylated EGFR, HER2 and HER3 were detected. Strikingly, the encapsulation
significantly reduced the phosphorylation of EGFR and HER3 (Figure 5.9E-F), whereas
HER2 phosphorylation remained unchanged (Figure 5.9G). This result emphasized the
role of the surrounding microenvironment in influencing the activity of certain RTK
receptor such as EGFR and HER3.
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Figure 5.9 The response of SkBr3 spheroids to EGF in 3D is stiffness independent.
(A) Encapsulated spheroids in PEG-MAL gels were serum-starved for 24 h before
stimulating with 100 ng/mL of EGF. After 1 h, EGF medium was replaced with serumfree medium. (B) EGFR phosphorylation peaked at 10 min and decreased over time. Both
(C) HER2 and (D) HER3 phosphorylation decreased during the EGF stimulation and
remained low even after EGF removal. Although there was a significant decrease in (E)
EGFR and (F) HER3 phosphorylation post encapsulation, there was not any significant
change in (G) HER2 phosphorylation due to encapsulation. Statistics are with respect to
time 0.
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5.4.4 Long-term exposure of SkBr3 to lapatinib results in different signaling
pathways activated in 2D and 3D
Since there was not any significant change in IC-50s across all platforms after
short term exposure of SkBr3s to lapatinib (Figure 5.4C), this motivated me to investigate
the influence 2D and 3D platforms on SkBr3s after being treated with lapatinib over a
long time period. SkBr3s were seeded on 2D plastic plates or encapsulated in PNIPAAm,
and then treated with lapatinib or DMSO control over 14 days. They were serum-starved
before being simulated with 10% FBS medium for 15 minutes. Phosphorylation of
EGFR, HER2, HER3, HER4, IGF1R, and IR were detected, whereas HGFR
phosphorylation was equal to the blank. Interestingly, lapatinib treated cells had
significantly lower phosphorylation of EGFR, HER2 and HER3 in both 2D and 3D as
compared with the control (Figures 5.10A-C). However, the IR phosphorylation of
lapatinib treated cells was significantly higher than the control in 2D, but similar to the
control in 3D (Figure 5.10D). The phosphorylation of HER4 and IGF1R were the same
between the control and treated cells for both 2D and 3D (Figures 5.10E-F). When
quantifying the downstream signaling molecules ERK, JNK, and Akt for the same
samples, strikingly, the phophorylation pattern of JNK (Figure 5.11A) was similar to that
of EGFR (compare Figures 5.10A and 5.11A). Both had a significant higher
phophorylation level of 2D control cells as opposed to the rest of the conditions (one-way
ANOVA). JNK phosphorylation was lower for lapatinib treated cells in 2D, but it was not
significantly different between the control and treated cells in 3D. ERK phosphorylation
displayed an opposite trend with lapatinib treated cells higher in 2D and lower in 3D
(Figure 5.11B), and there was not any difference in Akt phosphorylation between the
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control and treated cells in both 2D and 3D. Although the change in platfrom did not
cause any significant difference in SkBr3 response to lapatinib for a short-term exposure,
the type of platform did influence the activity of several signaling molecules (IR and
ERK) in SkBr3 cells after long-term exposure to lapatinib.
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Figure 5.10 Phosphorylation of RTK receptors of SkBr3 cells under serum
stimulation. Cells were cultured in 2D plastic plate or encapsulated in 3D PNIPAAm.
Cells were treated with 1.25 uM of lapatinib or DMSO control for 14 days followed by
serum-starvation and serum-stimulation. Phosphorylation level of (A) EGFR, (B) HER2,
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5.5 Discussion
I have identified that the IC-50s of SkBr3s treated with either sorafenib or
temsirolimus and 231s treated with either sorafenib or lapatinib were sensitive to the
change in platform and medium. The IC-50s of both cell lines were insensitive to the
change in platform or medium when treated with doxorubicin, which induces cell death
by DNA intercalation and topoisomerase II inhibition. Although spheroids can capture
many microenvironmental features of an in vivo tumor [28], cells in spheroids are not
neccessarily more drug resistant than cells cultured on monolayers. Ewing sarcoma tumor
cells cultured to form spheroids in 3D PCL scaffolds were 228-fold more resistant to
doxorubicin than 2D monolayer cells, and this is not due to poor drug penetration into the
innermost cell layer [29]. However, ovarian cancer spheroids grown in PEG-based
hydrogels were approximately 2.5-fold more resistant to cisplatin than 2D monolayer,
which causes apoptosis by crosslinking DNA [6]. Camptothecin (inhibitor to
topoisomerase I), fluorouracil (inhibitor to DNA synthesis) [30], and some derivatives of
imidazoacridinone (inhibitor to topoisomerase II) [31] were found to have similar
cytotoxic effects to cells cultured as monolayers or as spheroids. Thus, multiple different
drugs, which share similar targets (DNA intercalation or topoisomerase inhibition), can
have different or similar cytotoxic effects to cells in monolayer or spheroid. In my case, I
observed that doxorubicin had a similar effect on both cell types across all testing
platforms.
Interestingly, variations in both platform and medium were found to have large
effects on both cell lines when treated with sorafenib. ERK signaling, which is targeted
by sorafenib, was implicated in ECM stiffening in both 2D and 3D [26,32,33], and cancer
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cells on stiffer substrates were more resistant to sorafenib [16]. This suggests that the
Raf/MEK/ERK pathway could be sensitive to the change in microenvironment. Indeed,
both cell lines' response to sorafenib were highly sensitive to the type of platform. The
Raf/MEK/ERK pathway is also one of the key downstream signaling pathways of RTK
receptors [34], which can be activated by growth factors in serum. This could be an
explanation for the sensitivity of both cell lines to medium when treated with sorafenib.
Although PI3K/Akt/mTOR is another major signaling pathway downstream of
RTK activation [34], only SkBr3 spheroids showed higher IC-50s when treated with
temsirolimus, which inhibits mTOR, in serum supplemented medium (Figure 5.4D).
Moreover, the temsirolimus IC-50s of SkBr3 cells were more sensitive to variation in
platform than 231 cells. Both Raf/MEK/ERK and PI3K/Akt/mTOR pathways are
responsible for proliferation of HER2-overexpressing cells [35], whereas
Ras/Raf/MEK/ERK could be the main driver of 231 cell proliferation due to its B-Raf
and K-Ras mutation [36,37]. In the basal signaling protein profiles identified by Niepel et
al., phosphorylated Akt in the SkBr3s is nearly 40-fold higher than the 231s, whereas
phosphorylated ERK is similar for both cell types [38]. SkBr3 cells were shown to switch
from PI3K/Akt signaling to MEK/ERK signaling in 3D Matrigel, whereas both pathways
were activated in 2D [39], and inhibition of PI3K resulted in enhanced MEK/ERK
signaling [40]. These reports support my observation that inhibition of Akt/mTOR
signaling in SkBr3s, but not 231s, was sensitive to the change in platform.
When treating with lapatinib, which targets both HER2 and EGFR, 231s’ IC-50s
were sensitive to variations in both platform and medium. Since 231 cells overexpress
EGFR [41,42], it can be implied that EGFR signaling in 231 cells is sensitive to the type
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of platform and medium. Luca et al. also found that many colorectal cancer cell lines had
lower EGFR gene expression when cultured in 3D laminin-rich ECM [43]. SkBr3
response to lapatinib was insensitive to the change in both platform and medium. Thus, it
can be implied that the activities of EGFR and HER2 in SkBr3s were not sensitive to the
change in platform and medium. Further experiments confirmed that HER2
phosphorylation was not sensitive to modulus (Figure 5.9C), nor encapsulation (Figure
5.9 F), nor platform (2D vs. 3D in Figure 5.10B). EGFR phosphorylation of SkBr3 in 3D
was not affected by stiffness (Figure 5.9B), whereas EGFR phosphorylation was higher
on stiffer substrates [26], its phosphorylation on 2D plastic surface was 7-fold higher than
in 3D gels (Figure 5.10A). However, in SkBr3 cells, EGFR protein expression was much
lower than 231 cells, and their HER2 protein expression was very high [42]. Thus, the
signaling from HER2 may outweigh the effect from EGFR signaling in SkBr3s. As a
result, the IC-50s of lapatinib treated SkBr3 were less sensitive to the change in
microenvironment as opposed to those of 231 cells, which express only EGFR.
Unlike HER2 phosphorylation, which was not sensitive to the change in the
surrounding microenvironment, HER3 phosphorylation in SkBr3 spheroids decreased
significantly upon encapsulation (Figure 5.9E). Among the HER-family, HER3 is the
only member that does not have tyrosine kinase activity upon binding its ligand
heregulin, and it needs to heterodimerize with the other HER-family members in order to
be activated [44]. In 2D, HER3 was found to heterodimerize with HER2 as an oncogenic
unit to drive tumor cell proliferation [45]. It is possible that encapsulation could disrupt
the heterodimerization of HER3 and lead to a decrease in its phosphorylation, and this
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could cause an attenuation of the downstream PI3K/Akt signaling. In fact, Weigelt et al.
found that Akt phosphorylation of SkBr3s in 3D Matrigel was abolished [39].
Reduction of EGFR and HER3 phosphorylation during cell encapsulation may
have a profound impact on future research of HER-family receptors. Various methods
has been developed to induce 3D spheroid formation by allowing cell aggregation on
non-adherent surfaces such as the hanging drop method [46], agarose [9] or PDMS [10]
coated plates, or thin film PDMS micropatterning [15]. An encapsulation model may be
more relevant because tumor cells are tightly packed within the tumor microenvironment,
and encapsulation status could affect the activity of certain RTK receptors such as EGFR
and HER3.
Interestingly, during EGF stimulation, both HER2 and HER3 phosphorylation
decreased concurrently with EGFR activation. It is common that EGFR, upon EGF
binding, will heterodimerize with HER2 and subsequently lead to phosphorylation in
both receptors that results in activation of PI3K/Akt and Ras/Raf/MEK/ERK pathways
[35]. What I observed here suggests a mechanism of EGFR homodimerization and
possibly a disruption of HER2-HER3 complexes, which leads to a reduction in
phosphorylation level of both receptors. Similarly, after EGF stimulation in 2D,
Brockhoff et al. found a formation of EGFR-HER2 receptors complexes with BT474
cells, but not with SkBr3 cells, and the authors suggested an EGFR-EGFR
homodimerization mechanism in SkBr3 cells due to the higher number of available
EGFRs on the surface of these cells [47]. However, the authors observed a high amount
of HER2-HER3 heterodimers and constitutively activated Akt regardless of stimulation.
Taken together, these results also support my previous conclusion regarding the

179

sensitivity of HER2-HER3 interaction to the surrounding encapsulating
microenvironment. Although the phosphorylation of SkBr3 spheroids under EGF
stimulation is independent of modulus, SkBr3 spheroids in the soft gels proliferated
significantly more than those in stiffer gels, and this trend was consistent with the 231s,
and from others [24,25]. This effect can be attributed to the larger solid stress in stiffer
gels, and this stress on the spheroids can limit the spheroid proliferation [48–50]. The in
vivo tumor is also subjected to solid stress induced by stiff collagen fibers, which provide
tensile strength to the tissue, and hyaluronic acid, which provides the compressive
resistance due to its ability to hold water [51]. Thus, it is necessary to take into account
the effect from the solid stress as this can influence cell response to drug treatment, and
this solid stress is lacking from unencapsulated spheroid models.
Although short term exposure to lapatinib across various 2D and 3D platforms did
not show any significant variation in IC-50, long-term exposure to lapatinib showed some
differences in phosphorylation of certain signaling molecules across 2D plastic plate and
3D PNIPAAm. Upon serum stimulation, phosphorylation levels of EGFR, HER2, and
HER3 in lapatinib treated cells were significantly lower than the control for both
platforms, and Jegg et al. also observed similar phenomena with long-term lapatinibtreated SkBr3 on 2D [52]. However, IR phosphorylation of lapatinib-treated cells in 2D
increased significantly compared with the control but not in 3D (Figure 5.10D). Since IR
is capable of activating downstream signaling pathways such as Ras/Raf/MEK/ERK and
PI3K/Akt/mTOR [53], this corresponds with the increase in downstream ERK activation
in lapatinib treated cells in 2D (Figure 5.11B). Liu et al. identified the activation of Akt
and ERK due to an upregulation of the upstream AXL receptor as a mechanism for
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survival of lapatinib resistance BT474 cells in 2D [54], whereas Jegg et al. identified the
activation of mTOR independent of PI3K/Akt signaling as a mechanism for lapatinib
resistance in SkBr3 cells. However, the methods of creating lapatinib resistant cells
between the authors were also really different. In my case, exposure to lapatinib for 14
days was not long enough to create an established lapatinib resistant cell line (Figure
5.12) despite similar observable trends, which EGFR, HER2, and HER3 was downregulated in long-term lapatinib treated cells, with both Liu et al. and Jegg et al..
Nevertheless, 14 days of lapatinib exposure was enough for me to see a different pattern
of SkBr3 response between 2D and 3D with IR and ERK activation. The pattern of EGFR
activation was similar to JNK activation with very high phosphorylation on 2D and low
phosphorylation in 3D. This could be indicative of EGFR activating JNK under EGF
stimulation since EGF stimulation is known to activate PI3K/Akt and
Ras/Raf/MEK/ERK [55] as well as JNK through Ras/Rac1 pathway [56,57].
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Figure 5.12 Lapatinib treated and DMSO control SkBr3 spheroids have similar IC50s. SkBr3s were cultured in PNIPAAm for 6 days (DMSO) and 14 days (lapatinib) to
create spheroids of similar sizes since cells cultured with lapatinib grew at a slower rate.
Spheroids were transfered to 3 kPa gels and treated with laptinib.
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5.6 Conclusions
Overall, through testing 3 targeted drugs and 1 cytotoxic drug with 2 cell lines
across multiple platforms, I found that the sensitivity of cell-drug interaction to the
platform or medium is dependent on both drug type and cell type. The IC-50s of SkBr3s
were sensitive to platform type when treated with temsirolimus and sorafenib. The IC-50s
of 231s were sensitive to platform type when treated with sorafenib and lapatinib.
Variation in platform did not matter for both 231s and SkB3s when treated with
doxorubicin. I also found that HER3 and EGFR activation were sensitive to the
surrounding microenvironment, whereas HER2 phosphorylation is not. Long-term
exposure of SkBr3 to lapatinib caused distinct patterns of IR and ERK signaling observed
in 2D, but not in 3D. My results highlight the importance of understanding the cell type
and drug mechanism in choosing the relevant biomaterial system for studying of cell
response to drugs.
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CHAPTER 6

SUMMARY AND CONCLUSIONS

6.1 Summary
Throughout this thesis, the hypothesis that the physicochemical cues from the
ECM can promote drug resistance in cancer cells has been tested. First, various 2D and
3D biomaterial systems were developed and applied to test the hypothesis. Second,
cancer cells' response to sorafenib on 2D biomaterials with varying material and integrin
binding properties were probed. Finally, cancer cells were tested with different drugs
across various types of 2D and 3D microenvironments.
6.1.1 Biomaterial platforms
In Chapter 2, a novel hydrophilic material, PEG-PC, was developed, and its
properties were characterized. The hydrogel system was shown to have a tunable
mechanical range from 1 to 10,000 kPa and more hydrophilic than PEG alone. Different
methods were utilized to couple full-length matrix proteins to the gel surface. Chapter 3
described the adaptation of PEG-PC, PEG, and PAA hydrogels to the 96-well plate
format for high-throughput applications. Matrix proteins were coupled to these hydrogels
in the 96-well plate by using a heterobifunctional crosslinker. The gels' moduli were 6,
23, 50, 165, and 400 kPa. Chapter 5 detailed the adaptation of 3D biomaterial systems.
PNIPAAm-PEG is a thermal-reversible gel which was used to support the long-term
culture and formation of 3D spheroids. Cell-drug interaction in 3D was studied with cells
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or spheroids encapsulated in the PEG-MAL gels. The mechanical property of this 3D gel
system was tunable, and two different moduli being used were 3 and 5 kPa. Short
bioactive peptide sequence CRGD was also incorporated into the PEG-MAL gel system.
6.1.2 Matrix stiffness and integrin binding regulate the drug response in 2D
As described in chapter 3 and 4, most of cell lines were more resistant to
sorafenib when binding to collagen-rich matrix as compared with binding to basement
membrane matrix. Chapter 4 detailed the response of similar cell lines to sorafenib when
placed on 2D high-throughput platforms coupled with either collagen-rich or basement
membrane ECM. Cells on stiffer gels were more resistant to sorafenib than those on
softer gels. Although cells on stiffer gels are known to be more proliferative, this
stiffness-induced drug resistance was found to be independent of proliferation and not
related to the canonical Rho-ROCK pathway. Instead, this drug resistance was mediated
by β1 integrin and JNK activation, and co-administering sorafenib with inhibitor to either
of β1 integrin or JNK abolished the stiffness-induced drug resistance.
6.1.3 The role of biomaterial platforms in controlling cellular response to drugs
Chapter 5 described the studying of cell-drug interaction across varying types of
2D and 3D platforms and identified that the sensitivity of cell-drug interaction to
microenvironment is dependent on both drug type and cell type. Although cell response
to drug was found to be strongly regulated by material modulus in 2D, the effect on the
IC-50s from changing platforms and medium outweighed the effect from varying
modulus when comparing across different types of platform, medium, and modulus.
Changing in platform and medium affects how SkBr3 cells' response to sorafenib and
temsirolimus, and 231 cells' response to sorafenib and lapatinib, whereas both cell types'
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response to doxorubicin are independent of platform, medium, and modulus conditions.
Both HER3 and EGFR receptors were found to be sensitive to the microenvironment, but
not HER2 receptor.

6.2 Conclusions
The results presented in this dissertation support the hypothesis that the
interaction between cancer cells and the microenvironment can mediate survival signals
to cancer cells in the presence of chemotherapeutics. The stiffness-induced sorafenib
resistance on 2D substrates is independent of the change in cytoskeletal networks that
could influence the canonical Rho/ROCK signaling, but instead depending on β1 integrin
and JNK activation. This finding elucidates a new mechanism through which 2D matrix
stiffness can modulate cell behavior through pathways that are not related to those that
regulate cytoskeletal assembly. In 3D, matrix stiffness does not affect the drug response
as much as other factors such as cell-cell contact or medium condition, and the influence
of these factors to drug response is also dependent on drug type and cell type.
The results from this dissertation can have a great impact on future research
regarding developing preclinical models for cancer drug discovery. First, a better
understanding of how biomaterial platforms regulate drug response in cancer cells may
guide future effort in designing better model for preclinical drug development, and
having the relevant preclinical model that is more predictive of in vivo outcome will save
both time and money. Secondly, this research has created and applied separate in vitro
model systems including a novel biomaterial with an extremely wide mechanical range
that is suitable for many other applications, various 2D high-throughput biomaterial
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platforms for studies of cell-drug interaction and mechanobiology, a 3D biomaterial
system to culture multi-cellular spheroids, and a 3D spheroid model which can be easily
tunable for mechanical, integrin binding, and MMP-degradable properties.

6.3 Future Considerations
6.3.1 Matrix stiffening and inflammation
As shown previously in Chapter 4, matrix stiffening triggers higher JNK
phosphorylation. Activation of JNK in hepatocyte is known to stimulate its production of
high-mobility group box 1 protein (HMGB1), S100 calcium binding proteins, heat-shock
proteins, and purine metabolites that can activate IKK-β and NF-κB of local Kuffer cells
and trigger these cells to produce pro-inflammatory cytokines [1]. Activation of JNK in
macrophages can inhibit the function of glucocorticoid receptors, thereby allowing NFκB to be activated and enhancing the production of proinflammatory cytokines and
chemokines by these cells [2]. The pro-inflammatory cytokines can promote the tumor
cell growth and attract the infiltration of other immune cells, and this infiltration in turn
makes the tumor microenvironment more inflammatory, which could exacerbate the
disease [3,4]. It is proposed here that activation of JNK in 231s on stiff substrate can
make these cells produce more pro-inflammatory cytokines and other factors.
Examination of condition medium of these cells cultured on stiff substrates may provide
insights into this phenomena.
6.3.2 Apoptotic signaling on stiffen matrix
In Chapter 4, cells on stiff substrates were shown to be more resistant to
sorafenib, and this was found to be independent of Rho/ROCK signaling and
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proliferation. JNK activation was found to be responsible for the survival of 231s, but not
SkBr3s. Both MAPK and Akt signaling in SkBr3 was not responsible for this cell line's
resistance to sorafenib. It is proposed that the down regulation of apoptotic signals
instead of activation of survival pathways could be responsible for sorafenib resistance
of SkBr3s on stiff substrates. Caspases are known to mediate intracellular apoptosis.
Caspases-8 and -10 are activated upon binding of death-inducing ligands such as FasL
and TNF [5], but in my case, these ligands were not included in the experiment. Thus,
down regulation of intrisic death pathway mediated by caspase-9 and downstream
caspase-3/-6/-7 [5] could be responsible for promoting sorafenib resistance. Growth
arrest could be another mechanism for survival of drug resistance cells. Activation of
CDK1 is important for cells to enter into M phase, which includes mitosis and
cytokinesis, from G2 phase [6]. Therefore, activity of CDK1 also should be probed in
order to truly understand the mechanism of sorafenib resistance.
6.3.3 Cadherin-mediated cell-cell contact and drug resistance
In Chapter 5, SkBr3 spheroids were observed to be much more resistant to
sorafenib, lapatinib, and temsirolimus than SkBr3 single cells. However, 231 spheroids's
IC-50s do not show a profound difference with single cells' IC-50s as much as those of
SkBr3 cells . It is proposed that cadherin-mediated cell-cell contact can promote a
stronger drug resistance in SkBr3 cells than in 231s cells. 231 is a more aggressive cell
type that can invade local tissue and metastasize distal organs; thus it could be infer that
survival of these cells can be less dependent on cell-cell contact as opposed to the less
aggressive SkBr3s. SkBr3s on monolayer do not express any of the major cadherins such
as E-cadherin, N-cadherin, P-cadherin, cadherin-11, whereas 231s only express cadherin-

196

11 [7]. However, SkBr3s were capable of forming tight spheroids in my 3D culture
system. Thus, the expression of cadherin in 3D and 2D can be different depending on the
microenvironment. Quantifying the expression of cadherins of these two cell types under
conditions as monolayer, single cell in 3D, and spheroid can provide insights into how
microenvironment regulates cadherin expression. Ligation of cadherins can mediate βcatenin signaling, and cadherins can also interact with other RTKs and subsequently
trigger survival pathways such as PI3K/Akt or MAPK [8]. These downstream signaling
pathways should be quantified to understand how microenvironment induces cadherin
expression and its downstream signaling.
6.3.4 Cell-cell communication and drug resistance
The interaction between tumor cells and other factors released by different cell
types can impart resistance to chemotherapeutics such as HGF is known to mediate
vemurafenib resistance [9,10]. Cancer associated fibroblasts also play a role in promoting
the growth of tumor cells [11]. Thus, it is important to identify the influence of fibroblast
in the spheroid formation. The 3D PNIPAAm culture system allows tumor cells to be cocultured with fibroblasts, which can be seeded on the plate surface. Tumor spheroids can
be collected separately from fibroblasts. A thorough examination of spheroids from coculture and mono-culture would include a gene expression analysis via reverse
transcription polymerase chain reaction (RT-PCR) or real-time quantitative reverse
transcription PCR (qRT-PCR), and their drug response should also be tested. Conditioned
medium of the co-culture system should be quantified with the Luminex assays and
compared with the mono-culture of spheroid and fibroblast alone. The drug response of
spheroids from the co-culture and mono-culture systems should also be tested and related
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to the gene expression results in order to identify the molecular targets that could be
responsible for the differences.
6.3.5 Nuclear shape and drug resistance
The enlargement of the nucleus was found to be associated with poorer prognosis
in breast cancer as the nuclear area increased with disease progression [12]. The change
in nuclear shape allows different rearrangements of chromatins, which may allow or
prohibit the accessibility of transcription factors to certain locations of the chromatins for
gene transcription. Thus, certain genes can be upregulated or downregulated, and this
results in different cell behaviors, and perhaps their response to drugs. Indeed, the
increase in nuclear volume and chromatin decondensation were found to be highly
correlated with DNA synthesis in endothelial cells [13], and smooth muscle cells that had
larger nuclear area were found to proliferate more [14]. Since cells in advanced stage of
breast cancer tend to be more drug resistant than those in earlier stage, it is proposed that
cells with larger nuclear areas can be more resistant to chemotherapeutics than those with
smaller areas. Preliminary data showed that the nuclear area and perimeter of cells are
changed when treating with doxorubicin (Figure 6.1A-D) and sorafenib (Figure 6.2A-D).
However, the trend was different between the two cell types, and the nuclei of cells
treated with doxorubicin had larger changes than those of cells treated with sorafenib
partially due to different drug's mechanisms. Doxorubicin is a chemotherapeutic drug that
can cause cell death by DNA intercalation and has to be localized in the nucleus to be
effective, whereas sorafenib is a kinase inhibitor that can inhibit Raf kinase in the
cytoplasm. Based upon these observations, drug treatment can cause a change in cellular
nucleus, thus, it is possible to infer the reverse that the change in the nucleus can also
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affect the effectiveness of drug treatment, especially the drugs that have to localize in the
nucleus to be effective. Micro-contact printing can be employed to pattern glass surface
with square or circular shapes that have different areas to control cell spreading, which in
turn controls the nuclear area. The change in cell spreading can alter the ratio of lamin A
and B, thereby affecting the nuclear mechanics, shape, and area; these changes play an
important role in cell proliferation and differentiation [15]. Thus, the relative of amount
lamin A and B of cells with different spreading area should be quantified. A partial
knock-down of lamin A (with siRNA) of cells with the same spreading area can also be
done to eliminate the effect of changing the cytoskeleton outside of the nucleus due to the
change in cell shape.
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Figure 6.1 The change in nuclear shape and area as a function of doxorubicin
treatment. Increasing in doxorubicin concentration increases 231s' (A) nuclear area and
(B) perimeter while decreasing Hs-578Ts' (C) nuclear area and (D) perimeter.
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Figure 6.2 The change in nuclear shape and area as a function of sorafenib
treatment. Increasing in sorafenib concentration slightly decreases 231s' (A) nuclear area
and (B) perimeter while slightly increasing Hs-578Ts' (C) nuclear area and (D) perimeter.
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